



Curriculum Vitae

Personal information **Andreas Scorilas**

Work experience

2014 – Athens , Greece

PROFESSOR – NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS (NKUA), GREECE.

Professor of Clinical Biochemistry, Department of Biochemistry and Molecular Biology, National and Kapodistrian University of Athens (NKUA), Greece.

Head, Molecular Analysis and Cancer Biomarker Research Unit, Department of Biochemistry and Molecular Biology, Faculty of Biology, NKUA, Athens, Greece.

Director, Post Graduate Program: Clinical Biochemistry-Molecular Diagnostics, NKUA, Athens, Greece

Scientific Records

>**400** publications in international peer review scientific journals, including publications in top class journals such as *Clinical Chemistry*, *Journal of Clinical Oncology*, *Nature Medicine*, *Cancer Research*, *Clinical Cancer Research* etc.

Total Impact Factor **I.F > 2000 (5/ publication)**

>**20000 citations** (*Google Scholar*, Sept. 2023)

h-Index = 72 (*Google Scholar*, 65 in *Scopus*,)

10 Patent applications

>**300** publications in proceedings of international conferences.

>**5000** original complete gene entries in NCBI GeneBank, **6** gene cards.

6 Books and **12** Book chapters.

71 publications in Greek.

v Coordinator in >**20** accomplished national and international research grants.

Research Achievements

v Discovery, cloning and identification of the following novel cancer-related genes:

- The novel apoptotic *BCL2L12* gene
- The new carcinoembryonic antigen gene *CEAL1 (CEACAM19)*
- The *SR-A1* gene (*SCAF1*)
- *TSKS*, *AP2A1* etc

v Characterization and study of the kallikrein gene family members *KLK7*, *KLK11*, *KLK15*

v Elucidation of the clinical significance of kallikrein genes, L-Dopa decarboxylase (*DDC*) gene and other cancer-related

genes, in several human malignancies.

v Development of novel bioanalytical methodologies, useful in Biochemistry and Molecular Diagnostics.

Education and training

Department of Laboratory Medicine and Pathobiology, University of Toronto, Canada, Canada

POSTDOCTORAL TRAINING – Clinical Biochemistry - Pathobiology

1997 – G. Papanicolaou" Research Center of Oncology and Medical School, National and Kapodistrian University of Athens (NKUA). , Athens, Greece

PH.D – Biochemistry - Molecular Biology

University of Ioannina, Ioannina, Ioannina, Greece

B.SC.(HON) – Chemistry

LANGUAGE SKILLS

Mother tongue(s): GREEK

Other language(s): ENGLISH

DIGITAL SKILLS

Microsoft Office/ Microsoft Word/ Microsoft Excel/ Microsoft Powerpoint/ Outlook/ Zoom/ Skype/Facebook/ Instagram/ Google Drive/ LinkedIn/ Microsoft Teams/ Internet user/ Organizational and planning skills/ Good listener and communicator/ Google Docs/ Analytical skills/ Power Point Presenting

Additional information

Publications

A. Original Research Papers

1. Papadimitriou MA, Levis P, Kotronopoulos G, Stravodimos K, Avgeris M, **Scorilas A**. Preoperative Cell-Free DNA (cfDNA) in Muscle-Invasive Bladder Cancer Treatment Outcome. *Clin Chem*. 2023 Apr 3;69(4):399-410.
2. Adamopoulos PG, Athanasopoulou K, Boti MA, Dimitroulis G, Daneva GN, Tsiakanikas P, **Scorilas A**. Hybrid-seq deciphers the complex transcriptional profile of the human *BRCA1* DNA repair associated gene. *RNA Biol*. 2023 Jan;20(1):281-295.
3. Athanasopoulou K, Adamopoulos PG, **Scorilas A**. Unveiling the Human Gastrointestinal Tract Microbiome: The Past, Present, and Future of Metagenomics. *Biomedicines*. 2023 Mar 9;11(3):827.
4. Papadimitriou MA, Soureas K, Papanota AM, Tsiakanikas P, Adamopoulos PG, Ntanasis-Stathopoulos I, Malandrakis P, Gavriatopoulou M, Sideris DC, Kastritis E, Avgeris M, Dimopoulos MA, Terpos E, **Scorilas A**. miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma. *J Transl Med*. 2023 Apr 6;21(1):245.
5. Kontos CK, Hadjichambi D, Papatsirou M, Karousi P, Christodoulou S, Sideris DC, **Scorilas A**. Discovery and Comprehensive Characterization of Novel Circular RNAs of the Apoptosis-Related *BOK* Gene in Human Ovarian and Prostate Cancer Cells, Using Nanopore Sequencing. *Noncoding RNA*. 2023 Sep 24;9(5):57.
6. Karousi P, Kontos CK, Papakotsi P, Kostakis IK, Skaltsounis AL, **Scorilas A**. Next-generation sequencing reveals altered gene expression and enriched pathways in triple-negative breast cancer cells treated with oleuropein and oleocanthal. *Funct Integr Genomics*. 2023 Sep 14;23(4):299.
7. Papatsirou M, **Scorilas A**, Sideris DC, Kontos CK. Targeted nanopore sequencing for the identification of

novel *PRMT1* circRNAs unveils a diverse transcriptional profile of this gene in breast cancer cells. *Genes Dis.* 2023 May 18;11(2):589-592.

8. Soureas K, Papadimitriou MA, Panoutsopoulou K, Pilala KM, **Scorilas A**, Avgeris M. Cancer quiescence: non-coding RNAs in the spotlight. *Trends Mol Med.* 2023 Oct;29(10):843-858.
9. Liu Y, Gong W, Panoutsopoulou K, Singer-Cornelius T, Augustin K, Bronger H, Kiechle M, Dorn J, **Scorilas A**, Avgeris M, Magdolen V, Dreyer T. Association of high miR-27a, miR-206, and miR-214 expression with poor patient prognosis and increased chemoresistance in triple-negative breast cancer. *Am J Cancer Res.* 2023 Jun 15;13(6):2471-2487.
10. Kontos CK, Karousi P, Artemaki PI, Abdelgawad A, Dimitriadou A, Machairas NP, Sideris DC, Pappa V, **Scorilas A**, Batish M, Papageorgiou SG. Novel circular RNAs of the apoptosis-related BAX and BCL2L12 genes identified in a chronic lymphocytic leukemia cell line using nanopore sequencing. *FEBS Open Bio.* 2023 Oct;13(10):1953-1966.
11. Papasavva M, Amvrosiou S, Pilala KM, Soureas K, Christodoulou P, Ji Y, Stravodimos K, Xu D, **Scorilas A**, Avgeris M, Christodoulou MI. Deregulated Expression of *IL-37* in Patients with Bladder Urothelial Cancer: The Diagnostic Potential of the *IL-37e* Isoform. *Int J Mol Sci.* 2023 May 25;24(11):9258.
12. Gianniou DD, Sklirou AD, Papadimitriou MA, Pilala KM, Stravodimos K, Avgeris M, **Scorilas A**, Trougakos IP. Evaluation of the Small Heat Shock Protein Family Members *HSPB2* and *HSPB3* in Bladder Cancer Prognosis and Progression. *Int J Mol Sci.* 2023 Jan 30;24(3):2609.
13. Panoutsopoulou K, Magkou P, Dreyer T, Dorn J, Obermayr E, Mahner S, van Gorp T, Braicu I, Magdolen V, Zeillinger R, Avgeris M, **Scorilas A**. tRNA-derived small RNA 3'U-tRF^{ValCAC} promotes tumour migration and early progression in ovarian cancer. *Eur J Cancer.* 2022 Dec 10;180:134-145.
14. Panoutsopoulou K, Liu Y, Avgeris M, Dreyer T, Dorn J, Magdolen V, **Scorilas A**. Repression of miR-146a in predicting poor treatment outcome in triple-negative breast cancer. *Clin Biochem.* 2022 Dec 8:S0009-9120(22)00273-9.
15. Pilala KM, Papadimitriou MA, Panoutsopoulou K, Barbarigos P, Levis P, Kotronopoulos G, Stravodimos K, **Scorilas A**, Avgeris M. Epigenetic regulation of *MIR145* core promoter controls miR-143/145 cluster in bladder cancer progression and treatment outcome. *Mol Ther Nucleic Acids.* 2022 Oct 7;30:311-322.
16. Galani A, Markou A, Dimitrakopoulos L, Kontou A, Kostakis M, Kapes V, Diamantopoulos MA, Adamopoulos PG, Avgeris M, Lianidou E, **Scorilas A**, Paraskevis D, Tsiodras S, Dimopoulos MA, Thomaidis N. Delta SARS-CoV-2 variant is entirely

substituted by the omicron variant during the fifth COVID-19 wave in Attica region. *Sci Total Environ.* 2023 Jan 15;856(Pt 1):159062.

17. Trougakos IP, Terpos E, Alexopoulos H, Politou M, Paraskevis D, **Scorilas A**, Kastritis E, Andreakos E, Dimopoulos MA. COVID-19 mRNA vaccine-induced adverse effects: unwinding the unknowns. *Trends Mol Med.* 2022 Oct;28(10):800-802.
18. Sklirou AD, Gianniou DD, Karousi P, Cheimonidi C, Papachristopoulou G, Kontos CK, **Scorilas A**, Trougakos IP. High mRNA Expression Levels of Heat Shock Protein Family B Member 2 (*HSPB2*) Are Associated with Breast Cancer Patients' Relapse and Poor Survival. *Int J Mol Sci.* 2022 Aug 28;23(17):9758.
19. Papatsirou M, Diamantopoulos MA, Katsaraki K, Kletsas D, Kontos CK, **Scorilas A**. Identification of Novel Circular RNAs of the Human Protein Arginine Methyltransferase 1 (*PRMT1*) Gene, Expressed in Breast Cancer Cells. *Genes (Basel).* 2022 Jun 24;13(7):1133.
20. Athanasopoulou K, Adamopoulos PG, **Scorilas A**. Structural characterization and expression analysis of novel MAPK1 transcript variants with the development of a multiplexed targeted nanopore sequencing approach. *Int J Biochem Cell Biol.* 2022 Sep;150:106272.
21. Athanasopoulou K, Adamopoulos PG, Daneva GN, **Scorilas A**. Decoding the concealed transcriptional signature of the apoptosis-related BCL2 antagonist/killer 1 (BAK1) gene in human malignancies. *Apoptosis.* 2022 Dec;27(11-12):869-882.
22. Martzoukou O, Glekas PD, Avgeris M, Mamma D, **Scorilas A**, Kekos D, Amillis S, Hatzinikolaou DG. Interplay between Sulfur Assimilation and Biodesulfurization Activity in *Rhodococcus qingshengii* IGTS8: Insights into a Regulatory Role of the Reverse Transsulfuration Pathway. *mBio.* 2022 Aug 30;13(4):e0075422.
23. Tsiakanikas P, Adamopoulos PG, Tsirba D, Artemaki PI, Papadopoulos IN, Kontos CK, **Scorilas A**. High Expression of a tRNA^{Pro} Derivative Associates with Poor Survival and Independently Predicts Colorectal Cancer Recurrence. *Biomedicines.* 2022 May 12;10(5):1120.
24. Adamopoulos PG, Tsiakanikas P, Stolidi I, **Scorilas A**. A versatile 5' RACE-Seq methodology for the accurate identification of the 5' termini of mRNAs. *BMC Genomics.* 2022; 23(1):163.
25. Panoutsopoulou K, Dreyer T, Dorn J, Obermayr E, Mahner S, Gorp TV, Braicu I, Zeillinger R, Magdolen V, Avgeris M, **Scorilas A**. tRNA^{GlyGCC}-Derived Internal Fragment (i-tRF^{GlyGCC}) in Ovarian Cancer Treatment Outcome and Progression. 2021; 14(1):24.
26. Adamopoulos PG, Tsiakanikas P, Boti MA, **Scorilas A**. Targeted Long-Read Sequencing Decodes the Transcriptional Atlas of the Founding RAS Gene Family Members. *Int J Mol Sci.*

2021; 22(24):13298.

27. Karousi P, Papanota AM, Artemaki PI, Liacos CI, Patseas D, Mavrianou-Koutsoukou N, Liosi AA, Kalioraki MA, Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastritis E, Dimopoulos MA, **Scorilas A**, Terpos E, Kontos CK. tRNA Derivatives in Multiple Myeloma: Investigation of the Potential Value of a tRNA-Derived Molecular Signature. *Biomedicines*. 2021; 9(12):1811.
28. Xagorari M, Marmarinos A, Kossiva L, Baka M, Doganis D, Servitzoglou M, Tsofia M, **Scorilas A**, Avgeris M, Gourgiotis D. Overexpression of the GR Riborepressor LncRNA GAS5 Results in Poor Treatment Response and Early Relapse in Childhood B-ALL. *Cancers (Basel)*. 2021; 13(23):6064.
29. Papanota AM, Karousi P, Kontos CK, Artemaki PI, Liacos CI, Papadimitriou MA, Bagratuni T, Eleutherakis-Papaiakovou E, Malandrakis P, Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastritis E, Avgeris M, Dimopoulos MA, **Scorilas A**, Terpos E. A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma. *Int J Mol Sci*. 2021; 22(23):13144.
30. Papadimitriou MA, Papanota AM, Adamopoulos PG, Pilala KM, Liacos CI, Malandrakis P, Mavrianou-Koutsoukou N, Patseas D, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Kastritis E, Avgeris M, Dimopoulos MA, Terpos E, **Scorilas A**. miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome. *Br J Cancer*. 2021; 126(1):79-90.
31. Diamantopoulos MA, Georgoulia KK, **Scorilas A**. Identification and expression analysis of ten novel small non-coding RNAs (sncRNAs) in cancer cells using a high-throughput sequencing approach. *Gene*. 2021; 809:146025.
32. Galani A, Aalizadeh R, Kostakis M, Markou A, Alygizakis N, Lytras T, Adamopoulos PG, Peccia J, Thompson DC, Kontou A, Karagiannidis A, Lianidou ES, Avgeris M, Paraskevis D, Tsioudras S, **Scorilas A**, Vasiliou V, Dimopoulos MA, Thomaidis NS. SARS-CoV-2 wastewater surveillance data can predict hospitalizations and ICU admissions. *Sci Total Environ*. 2022; 804:150151.
33. Adamopoulos PG, Athanasopoulou K, Tsiakanikas P, **Scorilas A**. A comprehensive nanopore sequencing methodology deciphers the complete transcriptional landscape of cyclin-dependent kinase 4 (CDK4) in human malignancies. *FEBS J*. 2022; 712-729.
34. Avgeris M, Adamopoulos PG, Galani A, Xagorari M, Gourgiotis D, Trougakos IP, Voulgaris N, Dimopoulos MA, Thomaidis NS, **Scorilas A**. Novel Nested-Seq Approach for SARS-CoV-2 Real-Time Epidemiology and In-Depth Mutational Profiling in Wastewater. *Int J Mol Sci*. 2021; 22(16):8498.
35. Trougakos IP, Terpos E, Zirou C, Sklirou AD, Apostolakou F, Gumeni S, Charitaki I, Papanagnou ED, Bagratuni T, Liacos CI, **Scorilas A**, Korompoki E, Papassotiriou I, Kastritis E, Dimopoulos

- MA. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. *BMC Med.* 2021; 19(1):208.
36. Papanota AM, Tsiakanikas P, Kontos CK, Malandrakis P, Liacos CI, Ntanasis-Stathopoulos I, Kanellias N, Gavriatopoulou M, Kastritis E, Avgeris M, Dimopoulos MA, **Scorilas A**, Terpos E. A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma. *Cancers (Basel)*. 2021; 13(15):3877.
37. Adamopoulos PG, Tsiakanikas P, Adam EE, **Scorilas A**. Unraveling novel survivin mRNA transcripts in cancer cells using an in-house developed targeted high-throughput sequencing approach. *Genomics*. 2021; 113(1 Pt 2):573-581.
38. Papadimitriou MA, Avgeris M, Levis P, Papasotiriou EC, Kotronopoulos G, Stravodimos K, **Scorilas A**. tRNA-Derived Fragments (tRFs) in Bladder Cancer: Increased 5'-tRF-LysCTT Results in Disease Early Progression and Patients' Poor Treatment Outcome. *Cancers*. 2021; 12(12):3661.
39. Boti MA, Adamopoulos PG, Tsiakanikas P, **Scorilas A**. Nanopore Sequencing Unveils Diverse Transcript Variants of the Epithelial Cell-Specific Transcription Factor Elf-3 in Human Malignancies. *Genes*. 2021; 12(6):839.
40. Gong W, Zhu C, Liu Y, Muckenhuber A, Bronger H, **Scorilas A**, Kiechle M, Dorn J, Magdolen V, Dreyer T. Elevated levels of both microRNA 378 (miR-378) and kallikrein-related peptidase 4 (KLK4) mRNA are associated with an unfavorable prognosis in triple-negative breast cancer. *Am J Transl Res*. 2021; 13(3):1594-1606.
41. Grafanaki K, Skeparnias I, Kontos CK, Anastasakis D, Korfiati A, Kyriakopoulos G, Theofilatos K, Mavroudi S, Magoulas G, Papaioannou D, **Scorilas A**, Stathopoulos C, Drinas D. Pharmacoepigonomics circuits induced by a novel retinoid-polyamine conjugate in human immortalized keratinocytes. *Pharmacogenomics J*. 2021;
42. Tsitsilonis OE, Paraskevis D, Lianidou E, Terpos E, Akalestos A, Pierros V, Kostaki EG, Kastritis E, Moutsatsou P, Politou M, **Scorilas A**, et al. SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response. *Vaccines (Basel)*. 2021; 9(3):207.
43. Katsaraki K, Adamopoulos PG, Papageorgiou SG, Pappa V, **Scorilas A**, Kontos CK.
A 3' tRNA-derived fragment produced by tRNA^{LeuAAG} and tRNA^{LeuTAG} is associated with poor prognosis in B-cell chronic lymphocytic leukemia, independently of classical prognostic factors. *Eur J Haematol*. 2021; 106(6):821-830.
44. Papatsirou M, Adamopoulos PG, Artemaki PI, Georganti

- VP, **Scorilas A**, Vassilacopoulou D, Kontos CK. Next-generation sequencing reveals alternative L-DOPA decarboxylase (DDC) splice variants bearing novel exons, in human hepatocellular and lung cancer cells. *Gene*. 2021; 768:145262.
45. Karousi P, Artemaki PI, Sotiropoulou CD, Christodoulou S, **Scorilas A**, Kontos CK. Identification of Two Novel Circular RNAs Deriving from BCL2L12 and Investigation of Their Potential Value as a Molecular Signature in Colorectal Cancer. *Int J Mol Sci*. 2020; 21(22):8867.
46. Artemaki PI, Papatsirou M, Boti MA, Adamopoulos PG, Christodoulou S, Vassilacopoulou D, **Scorilas A**, Kontos CK. Revised Exon Structure of l-DOPA Decarboxylase (DDC) Reveals Novel Splice Variants Associated with Colorectal Cancer Progression. *Int J Mol Sci*. 2020; 21(22):8568.
47. Skeparnias I, Anastasakis D, Grafanaki K, Kyriakopoulos G, Alexopoulos P, Dougenis D, **Scorilas A**, Kontos CK, Stathopoulos C. Contribution of miRNAs, tRNAs and tRFs to Aberrant Signaling and Translation Dereglulation in Lung Cancer. *Cancers (Basel)*. 2020; 12(10):3056.
48. Tsitsilonis OE, Paraskevis D, Lianidou E, Pierros V, Akalestos A, Kastritis E, Moutsatsou P, **Scorilas A**, et al. Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report. *Life (Basel)*. 2020; 10(9):214.
49. Karousi P, Adamopoulos PG, Papageorgiou SG, Pappa V, **Scorilas A**, Kontos CK. A novel, mitochondrial, internal tRNA-derived RNA fragment possesses clinical utility as a molecular prognostic biomarker in chronic lymphocytic leukemia. *Clin Biochem*. 2020; 85:20-26.
50. Zisi Z, Adamopoulos PG, Kontos CK, **Scorilas A**. Identification and expression analysis of novel splice variants of the human carcinoembryonic antigen-related cell adhesion molecule 19 (CEACAM19) gene using a high-throughput sequencing approach. *Genomics*. 2020; 112(6):4268-4276.
51. Panoutsopoulou K, Avgeris M, Magkou P, Mavridis K, Dreyer T, Dorn J, Obermayr E, Reinthaller A, Michaelidou K, Mahner S, Vergote I, Vanderstichele A, Braicu I, Sehouli J, Zeillinger R, Magdolen V, **Scorilas A**. Institutionally-independent cohorts study of miR-181a prognostic value in serous ovarian carcinoma. *Int J Cancer*. 2020; 15;147(12):3560-3573.
52. Bagratuni T, Mavrianou N, Gavalas NG, Tzannis K, Arapinis C, Lontos M, Christodoulou MI, Thomakos N, Haidopoulos D, Rodolakis A, Kastritis E, **Scorilas A**, Dimopoulos MA, Bamias A. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer. *Eur J Cancer*. 2020;126:125-135.
53. Kalioraki MA, Artemaki PI, Sklirou AD, Kontos CK,

- Adamopoulos PG, Papadopoulos IN, Trougakos IP, **Scorilas A**. Heat shock protein beta 3 (HSPB3) is an unfavorable molecular biomarker in colorectal adenocarcinoma. *Mol Carcinog*. 2020;59(1):116-125.
54. Tatsi EB, Kanaka-Gantenbein C, **Scorilas A**, Chrousos GP, Sertedaki A. Next generation sequencing targeted gene panel in Greek MODY patients increases diagnostic accuracy. *Pediatr Diabetes*. 2020;21(1):28-39.
55. Nikcevic G, Drazilov SS, Djurasevic TK, Tomic N, Kontos CK, **Scorilas A**, Pavlovic S. Complex transcriptional regulation of the BCL2L12 gene: Novel, active promoter in K562 cells. *Gene*. 2020;750:144723.
56. Adamopoulos PG, Koukouzeli FE, Kontos CK, **Scorilas A**. Identification of six novel alternative transcripts of the human kallikrein-related peptidase 15 (KLK15), using 3'RACE and high-throughput sequencing. *Gene*. 2020;749:144708.
57. Artemaki PI, Sklirova AD, Kontos CK, Liosi AA, Gianniou DD, Papadopoulos IN, Trougakos IP, **Scorilas A**. High clusterin (CLU) mRNA expression levels in tumors of colorectal cancer patients predict a poor prognostic outcome. *Clin Biochem*. 2019;75:62-69.
58. Katsaraki K, Artemaki PI, Papageorgiou SG, Pappa V, **Scorilas A**, Kontos CK. Identification of a novel, internal tRNA-derived RNA fragment as a new prognostic and screening biomarker in chronic lymphocytic leukemia, using an innovative quantitative real-time PCR assay. *Leuk Res*. 2019; 87:106234.
59. Saleeb R, Kim SS, Ding Q, **Scorilas A**, Lin S, Khella HW, Boulos C, Ibrahim G, Yousef GM. The miR-200 family as prognostic markers in clear cell renal cell carcinoma. *Urol Oncol*. 2019;37(12):955-963.
60. Papadimitriou MA, Avgeris M, Levis PK, Tokas T, Stravodimos K, **Scorilas A**. Δ Np63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patient's post-treatment relapse and progression. *J Cancer Res Clin Oncol*. 2019; 145(12):3075-3087.
61. Avgeris M, Panoutsopoulou K, Papadimitriou MA, **Scorilas A**. Circulating exosomal miRNAs: clinical significance in human cancers. *Expert Rev Mol Diagn*. 2019; 19(11):979-995.
62. Panoutsopoulou K, Avgeris M, Mavridis K, Dreyer T, Dorn J, Obermayr E, Reinthaller A, Michaelidou K, Mahner S, Vergote I, Vanderstichele A, Braicu I, Sehouli J, Zeillinger R, Magdolen V, **Scorilas A**. miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study. *Carcinogenesis*. 2019; 17;41(4):442-451.
63. Adamopoulos PG, Tsiakanikas P, Kontos CK, Panagiotou A, Vassilacopoulou D, **Scorilas A**. Identification of novel alternative splice variants of the human L-DOPA decarboxylase (DDC) gene in human cancer cells, using high-throughput sequencing

approaches. *Gene*. 2019 30;719:144075.

64. Adamopoulos PG, Kontos CK, **Scorilas A**, Sideris DC. Identification of novel alternative transcripts of the human Ribonuclease κ (RNASEK) gene using 3' RACE and high-throughput sequencing approaches. *Genomics*. 2019, doi: 10.1016/j.ygeno.2019.06.010.
65. **Scorilas A**, Kontos CK, Adamopoulos PG. Molecular characterization, genomic structure and expression analysis of a gene (CATL1/CPT1C) encoding a third member of the human carnitine acyltransferase family. *Genomics*. 2019, 112(1):943-951.
66. Economopoulou P, Koutsodontis G, Avgeris M, Strati A, Kroupis C, Pateras I, Kirodimos E, Giotakis E, Kotsantis I, Maragoudakis P, Gorgoulis V, **Scorilas A**, Lianidou E, Psyrris A. HPV16 E6/E7 expression in circulating tumor cells in oropharyngeal squamous cell cancers: A pilot study. *PLoS One*. 2019; 14(5):e0215984.
67. Karousi P, Katsaraki K, Papageorgiou SG, Pappa V, **Scorilas A**, Kontos CK. Identification of a novel tRNA-derived RNA fragment exhibiting high prognostic potential in chronic lymphocytic leukemia. *Hematol Oncol*. 2019; 37(4):498-504.
68. Giannopoulou AF, Velentzas AD, Konstantakou EG, Avgeris M, Katarachia SA, Papandreou NC, Kalavros NI, Mpakou VE, Iconomidou V, Anastasiadou E, Kostakis IK, Papassideri IS, Voutsinas GE, **Scorilas A**, Stravopodis DJ. Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer. *Int J Mol Sci*. 2019 ;20(6).
69. Adamopoulos PG, Mavrogiannis AV, Kontos CK, **Scorilas A**. Novel alternative splice variants of the human protein arginine methyltransferase 1 (PRMT1) gene, discovered using next-generation sequencing. *Gene*. 2019; 699:135-144.
70. Avgeris M, Tsilimantou A, Levis PK, Rampias T, Papadimitriou MA, Panoutsopoulou K, Stravodimos K, **Scorilas A**. Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer. *Carcinogenesis*. 2019; 22;40(8):965-974.
71. Giannopoulou AF, Konstantakou EG, Velentzas AD, Avgeris SN, Avgeris M, Papandreou NC, Zoi I, Filippa V, Katarachia S, Lampidonis AD, Prombona A, Syntichaki P, Piperi C, Basdra EK, Iconomidou V, Papadavid E, Anastasiadou E, Papassideri IS, Papavassiliou AG, Voutsinas GE, **Scorilas A**, Stravopodis DJ. Gene-Specific Intron Retention Serves as Molecular Signature that Distinguishes Melanoma from Non-Melanoma Cancer Cells in Greek Patients. *Int J Mol Sci*. 2019; 20(4).
72. Papachristopoulou G, Malachias A, Devetzi M, Kamouza E, **Scorilas A**, Xynopoulos D, Talieri M. Uncovering the clinical impact of kallikrein-related peptidase 5 (KLK5) mRNA expression in the colorectal adenoma-carcinoma sequence. *Clin Chem Lab Med*. 2019, doi: 10.1515/cclm-2018-1010.
73. Christodoulou MI, Avgeris M, Kokkinopoulou I, Maratou E,

- Mitrou P, Kontos CK, Pappas E, Boutati E, **Scorilas A**, Fragoulis EG. Blood-based analysis of type-2 diabetes mellitus susceptibility genes identifies specific transcript variants with deregulated expression and association with disease risk. *Sci Rep*. 2019; 9(1):1512.
74. Rampias T, Karagiannis D, Avgeris M, Polyzos A, Kokkalis A, Kanaki Z, Kousidou E, Tzetis M, Kanavakis E, Stravodimos K, Manola KN, Pantelias GE, **Scorilas A**, Klinakis A. The lysine-specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer. *EMBO Rep*. 2019; 20(3).
75. Avgeris M, Tsilimantou A, Levis PK, Tokas T, Sideris DC, Stravodimos K, Ardavanis A, **Scorilas A**. Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients. *Br J Cancer*. 2018; 119(12):1477-1486.
76. Kladi-Skandali A, Sideris DC, **Scorilas A**. BCL2L12: a multiply spliced gene with independent prognostic significance in breast cancer. *Clin Chem Lab Med*. 2018; 57(2):276-287.
77. Tsiakanikas P, Giaginis C, Kontos CK, **Scorilas A**. Clinical utility of microRNAs in renal cell carcinoma: current evidence and future perspectives. *Expert Rev Mol Diagn*. 2018; 18(11):981-991.
78. Diamandis EP, **Scorilas A**, Prassas I, Plebani M. The International Society for Enzymology: a glorious history, a golden legacy. *Clin Chem Lab Med*. 2018; 56(11):275-276.
79. Adamopoulos PG, Kontos CK, Diamantopoulos MA, **Scorilas A**. Molecular cloning of novel transcripts of the adaptor-related protein complex 2 alpha 1 subunit (AP2A1) gene, using Next-Generation Sequencing. *Gene*. 2018; 15;678:55-64.
80. Avgeris M, Stamati L, Kontos CK, Piatopoulou D, Marmarinos A, Xagorari M, Baka M, Doganis D, Anastasiou T, Kosmidis H, Gourgiotis D, **Scorilas A**. BCL2L12 improves risk stratification and prediction of BFM-chemotherapy response in childhood acute lymphoblastic leukemia. *Clin Chem Lab Med*. 2018; 27;56(12):2104-2118.
81. Adamopoulos PG, Kontos CK, **Scorilas A**. Novel splice variants of the human kallikrein-related peptidases 11 (KLK11) and 12 (KLK12), unraveled by next-generation sequencing technology. *Biol Chem*. 2018; 399(9):1065-1071.
82. Adamopoulos PG, Raptis GD, Kontos CK, **Scorilas A**. Discovery and expression analysis of novel transcripts of the human SR-related CTD-associated factor 1 (SCAF1) gene in human cancer cells using Next-Generation Sequencing. *Gene*. 2018; 670:155-165.
83. Papageorgiou SG, Kontos CK, Tsiakanikas P, Stavroulaki G, Bouchla A, Vasilatou D, Bazani E, Lazarakou A, **Scorilas A**, Pappa V. Elevated miR-20b-5p expression in peripheral blood mononuclear cells: A novel, independent molecular biomarker of favorable prognosis in chronic lymphocytic leukemia. *Leuk Res*.

2018; 70:1-7.

84. Kladi-Skandali A, Mavridis K, **Scorilas A**, Sideris DC. Expressional profiling and clinical relevance of RNase κ in prostate cancer: a novel indicator of favorable progression-free survival. *J Cancer Res Clin Oncol*. 2018; 144(10):2049-2057.
85. Reuning U, Magdolen V, Courty Y, Clements JA, Yousef GM, **Scorilas A**, Talieri M, Diamandis EP. Manfred Schmitt (1947-2018). *Biol Chem*. 2018; 399(9):923-924.
86. Christodoulou MI, Tchoumtchoua J, Skaltsounis AL, **Scorilas A**, Halabalaki M. Natural alkaloids intervening the insulin pathway: new hopes for anti-diabetic agents? *Curr Med Chem*. 2018, doi: 10.2174/0929867325666180430152618.
87. Adamopoulos PG, Theodoropoulou MC, **Scorilas A**. Alternative Splicing Detection Tool-a novel PERL algorithm for sensitive detection of splicing events, based on next-generation sequencing data analysis. *Ann Transl Med*. 2018; 6(12):244.
88. Papachristopoulou G, Tsapralis N, Michaelidou K, Ardavanis-Loukeris G, Griniatsos I, **Scorilas A**, Talieri M. Human kallikrein-related peptidase 12 (KLK12) splice variants discriminate benign from cancerous breast tumors. *Clin Biochem*. 2018; 58:78-85.
89. Kourtis A, Adamopoulos PG, Papalois A, Iliopoulos DC, Babis GC, **Scorilas A**. Quantitative analysis and study of the mRNA expression levels of apoptotic genes BCL2, BAX and BCL2L12 in the articular cartilage of an animal model of osteoarthritis. *Ann Transl Med*. 2018; 6(12):243.
90. Diamantopoulos MA, Tsiakanikas P, **Scorilas A**. Non-coding RNAs: the riddle of the transcriptome and their perspectives in cancer. *Ann Transl Med*. 2018; 6(12):241.
91. Kontos CK, Avgeris M, Vassilacopoulou D, Ardavanis A, **Scorilas A**. Molecular effects of treatment of human colorectal cancer cells with natural and classical chemotherapeutic drugs: alterations in the expression of apoptosis-related BCL2 family members, including BCL2L12. *Curr Pharm Biotechnol*. 2018; 19(13):1064-1075.
92. Kalantzis ED, **Scorilas A**, Vassilacopoulou D. Evidence for L-Dopa decarboxylase activity in cancer cell cytotoxicity induced by Docetaxel and Mitoxantrone. *Curr Pharm Biotechnol*. 2018; 19(13):1087-1096.
93. Papadopoulos EI, Papachristopoulou G, Ardavanis A, **Scorilas A**. A comprehensive clinicopathological evaluation of the differential expression of microRNA-331 in breast tumors and its diagnostic significance. *Clin Biochem*. 2018; 60:24-32.
94. Papageorgiou SG, Diamantopoulos MA, Kontos CK, Bouchla A, Vasilatou D, Bazani E, **Scorilas A**, Pappa V. MicroRNA-92a-3p overexpression in peripheral blood mononuclear cells is an independent predictor of prolonged overall survival of patients with chronic lymphocytic leukemia. *Leuk Lymphoma*. 2018; 18:1-

- 10.
95. Tsiakanikas P, Kontos CK, Kerimis D, Papadopoulos IN, **Scorilas A**. High microRNA-28-5p expression in colorectal adenocarcinoma predicts short-term relapse of node-negative patients and poor overall survival of patients with non-metastatic disease. *Clin Chem Lab Med*. 2018; 56(6):990-1000.
96. Adamopoulos PG, Kontos CK, **Scorilas A**. Discovery of novel transcripts of the human tissue kallikrein (KLK1) and kallikrein-related peptidase 2 (KLK2) in human cancer cells, exploiting Next-Generation Sequencing technology. *Genomics*. 2018; doi: 10.1016/j.ygeno.2018.03.022.
97. Piatopoulou D, Avgeris M, Drakaki I, Marmarinos A, Xagorari M, Baka M, Pourtsidis A, Kossiva L, Gourgiotis D, **Scorilas A**. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia. *Ann Hematol*. 2018; 97(7):1169-1182.
98. Papageorgiou SG, Kontos CK, Diamantopoulos MA, Bouchla A, Glezou E, Bazani E, Pappa V, **Scorilas A**. MicroRNA-155-5p Overexpression in Peripheral Blood Mononuclear Cells of Chronic Lymphocytic Leukemia Patients Is a Novel, Independent Molecular Biomarker of Poor Prognosis. *Dis Markers*. 2017; 2017:2046545.
99. Haritos C, Michaelidou K, Mavridis K, Missitzis I, Ardavanis A, Griniatsos J, **Scorilas A**. Kallikrein-related peptidase 6 (KLK6) expression differentiates tumor subtypes and predicts clinical outcome in breast cancer patients. *Clin Exp Med*. 2018; 18(2):203-213.
100. Papachristopoulou G, Papadopoulos EI, Nonni A, Rassidakis GZ, **Scorilas A**. Expression Analysis of miR-29b in Malignant and Benign Breast Tumors: A Promising Prognostic Biomarker for Invasive Ductal Carcinoma with a Possible Histotype-Related Expression Status. *Clin Breast Cancer*. 2018; 18(4):305-312.
101. Adamopoulos PG, Kontos CK, **Scorilas A**. Molecular cloning of novel transcripts of human kallikrein-related peptidases 5, 6, 7, 8 and 9 (KLK5 - KLK9), using Next-generation sequencing. *Sci Rep*. 2017; 11;7(1):17299.
102. Tsikrika FD, Avgeris M, Levis PK, Tokas T, Stravodimos K, **Scorilas A**. miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients' risk for short-term relapse and progression. *Genes Chromosomes Cancer*. 2017; 57(3):150-161.
103. Kyriakou IK, Mavridis K, Kalogianni DP, Christopoulos TK, Ioannou PC, **Scorilas A**. Multianalyte quantitative competitive PCR on optically encoded microspheres for an eight-gene panel related to prostate cancer. *Anal Bioanal Chem*. 2017; 410(3):971-980.
104. Piatopoulou D, Avgeris M, Marmarinos A, Xagorari M, Baka M, Doganis D, Kossiva L, **Scorilas A**, Gourgiotis D. miR-125b

- predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment. *Br J Cancer*. 2017; 5;117(6):801-812.
105. Parmakelis A, Kotsakiozi P, Kontos CK, Adamopoulos PG, **Scorilas A**. The transcriptome of a "sleeping" invader: de novo assembly and annotation of the transcriptome of aestivating *Cornu aspersum*. *BMC Genomics*. 2017; 18(1):491.
 106. Rapti SM, Kontos CK, Christodoulou S, Papadopoulos IN, **Scorilas A**. miR-34a overexpression predicts poor prognostic outcome in colorectal adenocarcinoma, independently of clinicopathological factors with established prognostic value. *Clin Biochem*. 2017; 50(16-17):918-924.
 107. Adamopoulos PG, Kontos CK, **Scorilas A**. Identification and molecular cloning of novel transcripts of the human kallikrein-related peptidase 10 (KLK10) gene using next-generation sequencing. *Biochem Biophys Res Commun*. 2017; 10;487(4):776-781.
 108. Kontos CK, Tsiakanikas P, Avgeris M, Papadopoulos IN, Scorilas A. miR-15a-5p, A Novel Prognostic Biomarker, Predicting Recurrent Colorectal Adenocarcinoma. *Mol Diagn Ther*. 2017; 21(4):453-464.
 109. Tsangaris GT, Papathanasiou C, Adamopoulos PG, **Scorilas A**, Vorgias CE, Prodromou N, Stathopoulou FT, Stravopodis DJ, Anagnostopoulos AK. Pediatric Ependymoma: A Proteomics Perspective. *Cancer Genomics Proteomics*. 2017; 14(2):127-136.
 110. Khella HWZ, Daniel N, Youssef L, **Scorilas A**, Nofech-Mozes R, Mirham L, Krylov SN, Liandeau E, Krizova A, Finelli A, Cheng Y, Yousef GM. miR-10b is a prognostic marker in clear cell renal cell carcinoma. *J Clin Pathol*. 2017; 70(10):854-859.
 111. White NM, Masui O, Newsted D, **Scorilas A**, Romaschin AD, Bjarnason GA, Siu KW, Yousef GM. Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis. *Br J Cancer*. 2017; 4;110(5):1250-9.
 112. Kontos CK, Papageorgiou SG, Diamantopoulos MA, **Scorilas A**, Bazani E, Vasilatou D, Gkontopoulos K, Glezou E, Stavroulaki G, Dimitriadis G, Pappa V. mRNA overexpression of the hypoxia inducible factor 1 alpha subunit gene (HIF1A): An independent predictor of poor overall survival in chronic lymphocytic leukemia. *Leuk Res*. 2017; 53:65-73.
 113. Kapodistrias N, Mavridis K, Batistatou A, Gogou P, Karavasilis V, Sainis I, Briasoulis E, **Scorilas A**. Assessing the clinical value of microRNAs in formalin-fixed paraffin-embedded liposarcoma tissues: Overexpressed miR-155 is an indicator of poor prognosis. *Oncotarget*. 2017; 24;8(4):6896-6913.
 114. Kerimis D, Kontos CK, Christodoulou S, Papadopoulos IN, **Scorilas A**. Elevated expression of miR-24-3p is a potentially adverse prognostic factor in colorectal adenocarcinoma. *Clin*

Biochem. 2016; 50(6):285-292.

115. Diamantopoulos MA, Kontos CK, Kerimis D, Papadopoulos IN, **Scorilas A**. Upregulated miR-16 expression is an independent indicator of relapse and poor overall survival of colorectal adenocarcinoma patients. *Clin Chem Lab Med.* 2016; 1;55(5):737-747.
116. Galtsidis S, Logotheti S, Pavlopoulou A, Zampetidis CP, Papachristopoulou G, **Scorilas A**, Vojtesek B, Gorgoulis V, Zoumpourlis V. Unravelling a p73-regulated network: The role of a novel p73-dependent target, MIR3158, in cancer cell migration and invasiveness. *Cancer Lett.* 2017; 1;388:96-106.
117. Adamopoulos PG, Kontos CK, Tsiakanikas P, **Scorilas A**. Identification of novel alternative splice variants of the BCL2L12 gene in human cancer cells using next-generation sequencing methodology. *Cancer Lett.* 2016; 1;373(1):119-129.
118. Tokas T, Avgeris M, Alamanis C, **Scorilas A**, Stravodimos KG, Constantinides CA. Downregulated KLK13 expression in bladder cancer highlights tumor aggressiveness and unfavorable patients' prognosis. *J Cancer Res Clin Oncol.* 2016; 143(3):521-532.
119. Rapti SM, Kontos CK, Papadopoulos IN, **Scorilas A**. High miR-96 levels in colorectal adenocarcinoma predict poor prognosis, particularly in patients without distant metastasis at the time of initial diagnosis. *Tumour Biol.* 2016; 37(9):11815-11824.
120. Papageorgiou SG, Kontos CK, Foukas PG, Panopoulou E, Vasilatou D, Rapti SM, Gkontopoulos K, Bazani E, Panayiotides IG, Dimitriadis G, **Scorilas A**, Pappa V. BCL2L12 protein overexpression is associated with favorable outcome in diffuse large B-cell lymphoma patients in the rituximab era. *Leuk Lymphoma.* 2016; 57(9):2199-203.
121. Dalloneau E, Baroukh N, Mavridis K, Maillet A, Gueugnon F, Courty Y, Petit A, Kryza T, Del Rio M, Guyetant S, Castaneda DC, Dhommée C, Arnoult C, **Scorilas A**, Gouilleux-Gruart V, Heuzé-Vourc'h N. Downregulation of the neonatal Fc receptor expression in non-small cell lung cancer tissue is associated with a poor prognosis. *Oncotarget.* 2016; 23;7(34):54415-54429.
122. Giotakis AI, Kontos CK, Manolopoulos LD, Sismanis A, Konstadoulakis MM, **Scorilas A**. High BAX/BCL2 mRNA ratio predicts favorable prognosis in laryngeal squamous cell carcinoma, particularly in patients with negative lymph nodes at the time of diagnosis. *Clin Biochem.* 2016; 49(12):890-6.
123. Papadopoulos EI, Petraki C, Gregorakis A, Fragoulis EG, **Scorilas A**. Clinical evaluation of microRNA-145 expression in renal cell carcinoma: a promising molecular marker for discriminating and staging the clear cell histological subtype. *Biol Chem.* 2016; 1;397(6):529-39.
124. Nofech-Mozes R, Khella HW, **Scorilas A**, Youssef L, Krylov SN, Lianidou E, Sidiropoulos KG, Gabril M, Evans A, Yousef GM. MicroRNA-194 is a Marker for Good Prognosis in Clear Cell

Renal Cell Carcinoma. *Cancer Med.* 2016; 5(4):656-64.

125. Miltiades P, Lamprianidou E, Vassilakopoulos TP, Papageorgiou SG, Galanopoulos A, Kontos CK, Adamopoulos PG, Nakou E, Vakalopoulou S, Garypidou V, Papaioannou M, Hatjiharissi E, Papadaki HA, Spanoudakis E, Pappa V, **Scorilas AS**, Tsatalas C, Kotsianidis I. The Stat3/5 signaling biosignature in hematopoietic stem/progenitor cells predicts response and outcome in myelodysplastic syndrome patients treated with azacitidine. *Clin Cancer Res.* 2015; 15;22(8):1958-68.
126. Skourti E, Logotheti S, Kontos CK, Pavlopoulou A, Dimoragka PT, Trougkos IP, Gorgoulis V, **Scorilas A**, Michalopoulos I, Zoumpourlis V. Progression of mouse skin carcinogenesis is associated with the orchestrated deregulation of miR-200 family members, miR-205 and their common targets. *Mol Carcinog.* 2015; 55(8):1229-42.
127. Gabril M, Girgis H, **Scorilas A**, Rotondo F, Wala S, Bjarnason GA, Ding Q, Evans A, Tawedrous E, Pasic M, Finelli A, Al-Haddad S, Yousef GM. S100A11 is a potential prognostic marker for clear cell renal cell carcinoma. *Clin Exp Metastasis.* 2015; 33(1):63-71.
128. Vassilakopoulou M, Avgeris M, Velcheti V, Kotoula V, Rampias T, Chatzopoulos K, Perisanidis C, Kontos CK, Giotakis AI, **Scorilas A**, Rimm DL, Sasaki CT, Fountzilias G, Psyrris A. Evaluation of PD-L1 expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma. *Clin Cancer Res.* 2015; 1;22(3):704-13.
129. Luchini C, Veronese N, Solmi M, Cho H, Kim JH, Chou A, Gill AJ, Faraj SF, Chaux A, Netto GJ, Nakayama K, Kyo S, Lee SY, Kim DW, Yousef GM, **Scorilas A**, Nelson GS, Köbel M, Kalloger SE, Schaeffer DF, Yan HB, Liu F, Yokoyama Y, Zhang X, Pang D, Lichner Z, Sergi G, Manzato E, Capelli P, Wood LD, Scarpa A, Correll CU. Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. *Oncotarget.* 2015; 17;6(36):39088-97.
130. Papadopoulos EI, **Scorilas A**. Cisplatin and Paclitaxel Alter the Expression Pattern of miR-143/145 and miR-183/96/182 Clusters in T24 Bladder Cancer Cells. *Clin Transl Sci.* 2015; 8(6):668-75.
131. Kontos CK, Adamopoulos PG, Papageorgiou SG, Pappa V, **Scorilas A**. mRNA overexpression of kallikrein-related peptidase 14 (KLK14) is an independent predictor of poor overall survival in chronic lymphocytic leukemia patients. *Clin Chem Lab Med.* 2016; 54(2):315-24.
132. Michaelidou K, Ardavanis A, **Scorilas A**. Clinical relevance of the deregulated kallikrein-related peptidase 8 mRNA expression in breast cancer: a novel independent indicator of disease-free survival. *Breast Cancer Res Treat.* 2015; 152(2):323-36.
133. Karaliotas GI, Mavridis K, **Scorilas A**, Babis GC. Quantitative analysis of the mRNA expression levels of BCL2 and BAX genes

- in human osteoarthritis and normal articular cartilage: An investigation into their differential expression. *Mol Med Rep*; 2015; 12(3):4514-21.
134. White-Al Habeeb NM, Di Meo A, **Scorilas A**, Rotondo F, Masui O, Seivwright A, Gabril M, Girgis AH, Jewett MA, Yousef GM. Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma. *Clin Exp Metastasis*. 2015; 32(6):531-41.
 135. Stamati L, Avgeris M, Kosmidis H, Baka M, Anastasiou T, Piatopoulou D, **Scorilas A**, Gourgiotis D. Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patients' poor response to treatment and short-term relapse. *J Cancer Res Clin Oncol*. 2015; 141(11):2023-36.
 136. Adamopoulos PG, Kontos CK, Papageorgiou SG, Pappa V, **Scorilas A**. KLKB1 mRNA overexpression: A novel molecular biomarker for the diagnosis of chronic lymphocytic leukemia. *Clin Biochem*. 2015; 48(13-14):849-54.
 137. Papadopoulos EI, Yousef GM, **Scorilas A**. Gemcitabine impacts differentially on bladder and kidney cancer cells: distinct modulations in the expression patterns of apoptosis-related microRNAs and BCL2 family genes. *Tumour Biol*. 2015; 36(5):3197.
 138. Avgeris M, Mavridis K, Tokas T, Stravodimos K, Fragoulis EG, **Scorilas A**. Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment. *Carcinogenesis*. 2015; 36(5):528-37.
 139. Papadopoulos EI, Yousef GM, **Scorilas A**. Cytotoxic activity of sunitinib and everolimus in Caki-1 renal cancer cells is accompanied by modulations in the expression of apoptosis-related microRNA clusters and BCL2 family genes. *Biomed Pharmacother*. 2015; 70:33-40.
 140. Papadopoulos EI, Petraki C, Gregorakis A, Chra E, Fragoulis EG, **Scorilas A**. L-DOPA decarboxylase mRNA levels provide high diagnostic accuracy and discrimination between clear cell and non-clear cell subtypes in renal cell carcinoma. *Clin Biochem*. 2015; 48(9):590-5.
 141. Karamchandani JR, Gabril MY, Ibrahim R, **Scorilas A**, Filter E, Finelli A, Lee JY, Ordon M, Pasic M, Romaschin AD, Yousef GM. Profilin-1 expression is associated with high grade and stage and decreased disease-free survival in renal cell carcinoma. *Hum Pathol*. 2015; 46(5):673-80.
 142. Gueugnon F, Barascu A, Mavridis K, Petit-Courty A, Marchand-Adam S, Gissot V, **Scorilas A**, Guyetant S, Courty Y. Kallikrein-related peptidase 13: an independent indicator of favorable prognosis for patients with nonsmall cell lung cancer. *Tumour Biol*. 2015; 36(7):4979-86.
 143. Khella HW, **Scorilas A**, Mozes R, Mirham L, Lianidou E, Krylov SN, Lee JY, Ordon M, Stewart R, Jewett MA, Yousef GM. Low expression of miR-126 is a prognostic marker for metastatic

- clear cell renal cell carcinoma. *Am J Pathol*. 2015; 185(3):693-703.
144. Samaan S, Khella HW, Girgis A, **Scorilas A**, Lianidou E, Gabril M, Krylov SN, Jewett M, Bjarnason GA, El-said H, Yousef GM. miR-210 is a prognostic marker in clear cell renal cell carcinoma. *J Mol Diagn*. 2015; 17(2):136-44.
145. Adamopoulos PG, Kontos CK, Rapti SM, Papadopoulos IN, **Scorilas A**. miR-224 overexpression is a strong and independent prognosticator of short-term relapse and poor overall survival in colorectal adenocarcinoma. *Int J Oncol*. 2015; 46(2):849-59.
146. Tzouvaras A, Kladi-Skandali A, Michaelidou K, Zografos GC, Missitzis I, Ardavanis A, **Scorilas A**. BCL2L12: a promising molecular prognostic biomarker in breast cancer. *Clin Biochem*. 2014; 47(18):257-62.
147. Rampias T, Vgenopoulou P, Avgeris M, Polyzos A, Stravodimos K, Valavanis C, **Scorilas A**, Klinakis A. A new tumor suppressor role for the Notch pathway in bladder cancer. *Nature Medicine*. 2014; 20(10):1199-205.
148. Samaan S, Khella HW, Girgis A, **Scorilas A**, Lianidou E, Gabril M, Krylov SN, Jewett M, Bjarnason GA, El-Said H, Yousef GM. miR-210 Is a Prognostic Marker in Clear Cell Renal Cell Carcinoma. *J Mol Diagn*. 2014; 17(2):136-44.
149. Papadopoulos EI, Fragoulis EG, **Scorilas A**. Human l-DOPA decarboxylase mRNA is a target of miR-145: A prediction to validation workflow. *Gene*. 2014; 554(2):174-180.3.
150. Tzouvaras A, Kladi-Skandali A, Michaelidou K, Zografos GC, Missitzis I, Ardavanis A, **Scorilas A**. BCL2L12: A promising molecular prognostic biomarker in breast cancer. *Clin Biochem*. 2014; 47(18):257-62.
151. Vakrakou A, Devetzi M, Papachristopoulou G, Malachias A, **Scorilas A**, Xynopoulos D, Talieri M. Kallikrein-related peptidase 6 (KLK6) expression in the progression of colon adenoma to carcinoma. *Biol Chem*. 2014; 395(9):1105-17.
152. Avgeris M, Stravodimos K, **Scorilas A**. Loss of miR-378 in prostate cancer, a common regulator of KLK2 and KLK4, correlates with aggressive disease phenotype and predicts the short-term relapse of the patients. *Biol Chem*. 2014; 395(9):1095-104.
153. Alexopoulou DK, Kontos CK, Christodoulou S, Papadopoulos IN, **Scorilas A**. KLK11 mRNA expression predicts poor disease-free and overall survival in colorectal adenocarcinoma patients. *Biomark Med*. 2014; 8(5):671-85.
154. Girgis H, Masui O, White NM, **Scorilas A**, Rotondo F, Seivwright A, Gabril M, Filter ER, Girgis AH, Bjarnason GA, Jewett MA, Evans A, Al-Haddad S, Siu KM, Yousef GM Lactate dehydrogenase. A is a potential prognostic marker in clear cell renal cell carcinoma. *Mol Cancer*. 2014; 13:101.
155. Pavlopoulou A, **Scorilas A**. A comprehensive phylogenetic and

structural analysis of the carcinoembryonic antigen (CEA) gene family. *Genome Biol Evol* 2014; 6(6):1314-26.

156. Foteinou E, Kontos CK, Giotakis AI, **Scorilas A**. Low mRNA expression levels of kallikrein-related peptidase 4 (KLK4) predict short-term relapse in patients with laryngeal squamous cell carcinoma. *Biol Chem*. 2014; 395(9):1051-62.
157. Rampias T, Giagini A, Siolos S, Matsuzaki H, Sasaki CT, **Scorilas A**, Psyri A. RAS/ PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma. *Clin Cancer Res*. 2014; 20(11):2933-46.
158. Rapti SM, Kontos CK, Papadopoulos IN, **Scorilas A**. Enhanced miR-182 transcription is a predictor of poor overall survival in colorectal adenocarcinoma patients. *Clin Chem Lab Med*. 2014; 52(8):1217-27.
159. White NM, Masui O, Newsted D, **Scorilas A**, Romaschin AD, Bjarnason GA, Siu KW, Yousef GM. Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis. *Br J Cancer*. 2014; 110(5):1250-9.
160. Christodoulou S, Alexopoulou DK, Kontos CK, **Scorilas A**, Papadopoulos IN. Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma. *Tumour Biol*. 2014; 35(5):4673-85.
161. Theodorou M, Speletas M, Mamara A, Papachristopoulou G, Lazou V, **Scorilas A**, Katsantoni E. Identification of a STAT5 target gene, Dpf3, provides novel insights in chronic lymphocytic leukemia. *PLoS One*. 2013; 14;8(10):e76155.
162. Koumandou VL, **Scorilas A**. Evolution of the plasma and tissue kallikreins, and their alternative splicing isoforms. *PLoS One*. 2013; 8(7):e680742013.
163. Florou D, Patsis C, Ardavanis A, **Scorilas A**. Effect of doxorubicin, oxaliplatin and methotrexate administration on the transcriptional activity of BCL-2 family gene members in stomach cancer cells. *Cancer Biol Ther*. 2013; 14(7):587-96.
164. Foutadakis S, Avgeris M, Tokas T, Stravodimos K, **Scorilas A**. Increased BCL2L12 expression predicts the short-term relapse of patients with TaT1 bladder cancer following transurethral resection of bladder tumors. *Urol Oncol* 2013; 32(1):39.e29-36.
165. Kontos CK, Fendri A, Khabir A, Mokdad-Gargouri R, **Scorilas A**. Quantitative expression analysis and prognostic significance of the BCL2-associated X gene in nasopharyngeal carcinoma: a retrospective cohort study. *BMC Cancer*. 2013; 13:293.
166. Avgeris M, Stravodimos K, Fragoulis EG, **Scorilas A**. The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients. *Br J Cancer*. 2013; 108(12):2573-81.

167. Mavridis K, Stravodimos K, **Scorilas A**. Quantified KLK15 Gene Expression Levels Discriminate Prostate Cancer From Benign Tumors and Constitute a Novel Independent Predictor of Disease Progression. *Prostate*. 2013; 73(11):1191-201.
168. Michaelidou K, Tzovaras A, Missitzis I, Ardavanis A, **Scorilas A**. The expression of the CEACAM19 gene, a novel member of the CEA family, is associated with breast cancer progression. *Int J Oncol*. 2013; 42(5):1770-7.
169. Alexopoulou DK, Papadopoulos IN, **Scorilas A**. Clinical significance of kallikrein-related peptidase (KLK10) mRNA expression in colorectal cancer. *Clin Biochem*. 2013; 46(15):1453-61.
170. Mavridis K, Stravodimos K, **Scorilas A**. Down-regulation and prognostic significance of microRNA 224 (miR-224) expression in prostate cancer. *Clin Chem*. 2013; 59(1):261-9.
171. Korbakis D, Fragoulis EG, **Scorilas A**. Quantification and study of the L-DOPA decarboxylase expression in gastric adenocarcinoma cells treated with chemotherapeutic substances. *Anti-Cancer Drugs*. 2013; 24(3):291-9.
172. [Papachristopoulou G](#), [Talieri M](#), [Scorilas A](#). Significant alterations in the expression pattern of kallikrein-related peptidase genes KLK4, KLK5 and KLK14 after treatment of breast cancer cells with the chemotherapeutic agents epirubicin, docetaxel and methotrexate. *Tumour Biol*. 2013; 34(1):369-78.
173. Karan-Djurasevic T, Palibrk V, Zukic B, Spasovski V, Glumac I, Colovic M, Colovic N, Jurisic V, **Scorilas A**, Pavlovic S, Tosic N. Expression of Bcl2L12 in chronic lymphocytic leukemia patients: association with clinical and molecular prognostic markers. *Med Oncol*. 2013; 30(1):405.
174. Lichner Z, **Scorilas A**, White NMA, Girgis AH, Rotstein L, Wiegand KC, Latif A, Chow C, Huntsman D, Yousef GM. The Chromatin Remodeling Gene, *ARID1A* is a New Prognostic Marker in Clear Cell Renal Cell Carcinoma. *Am J Pathol*. 2013; 182(4):1163-70.
175. Florou D, Papadopoulos IN, Fragoulis EG, **Scorilas A**. L-Dopa decarboxylase (DDC) constitutes an emerging biomarker in predicting patients' survival with stomach adenocarcinomas. *J Cancer Res Clin Oncol*. 2013; 139(2):297-306.
176. Devetzi M, Trangas T, **Scorilas A**, Xynopoulos D, Talieri M. Parallel overexpression and clinical significance of Kallikrein-related peptidases 7 and 14 (*KLK7* & *KLK14*) in colon cancer. *Thromb Haemost*. 2012; 109(4):716-25.
177. Kontos CK, Chantzis D, Papadopoulos IN, **Scorilas A**. Kallikrein-related peptidase 4 (*KLK4*) mRNA predicts short-term relapse in colorectal adenocarcinoma patients. *Cancer Lett*. 2013; 330(1):106-122.
178. [Geomela PA](#), [Kontos CK](#), [Yiotakis I](#), [Fragoulis EG](#), [Scorilas A](#).

L-DOPA decarboxylase mRNA expression is associated with tumor stage and size in head and neck squamous cell carcinoma: a retrospective cohort study. [BMC Cancer](#). 2012; 20,12(1):484.

179. Florou D, Mavridis K, **Scorilas A**. The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents. *Tumour Biol*. 2012; 33(6):2069-78.
180. Patsis C, Glyka V, Yiotakis I, Fragoulis EG, **Scorilas A**. l-DOPA Decarboxylase (DDC) Expression Status as a Novel Molecular Tumor Marker for Diagnostic and Prognostic Purposes in Laryngeal Cancer. *Transl Oncol*. 2012; 5(4):288-96.
181. Geomela PA, Kontos CK, Yiotakis I, **Scorilas A**. Quantitative expression analysis of the apoptosis-related gene, BCL2L12, in head and neck squamous cell carcinoma. *J Oral Pathol Med*. 2012; 42(2):154-61.
182. Thomadaki H, Floros KV, Pavlovic S, Tomic N, Gourgiotis D, Colovic M, **Scorilas A**. Overexpression of the novel member of the BCL2 gene family, BCL2L12, is associated with the disease outcome in patients with acute myeloid leukemia. *Clin Biochem*. 2012; 45(16-17):1362-7.
183. Kontos CK, **Scorilas A**. Molecular cloning of novel alternatively spliced variants of BCL2L12, a new member of the BCL2 gene family, and their expression analysis in cancer cells. *Gene*. 2012; 505(1):153-66.
184. Faragalla H, Youssef YM, **Scorilas A**, Khalil B, White NM, Mejia-Guerrero S, Khella H, Jewett MA, Evans A, Lichner Z, Bjarnason G, Sugar L, Attalah MI, Yousef GM. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. *J Mol Diagn*. 2012; 14(4):385-92.
185. Koutalellis G, Stravodimos K, Avgeris M, Mavridis K, **Scorilas A**, Lazaris A, Constantinides C. L-dopa decarboxylase (DDC) gene expression is related to outcome in patients with prostate cancer. *BJU Int*. 2012; 110(6 Pt B):267-73.
186. Thanopoulou E, Kotzamanis G, Pateras IS, Ziras N, Papalambros A, Mariolis-Sapsakos T, Sigala F, Johnson E, Kotsinas A, **Scorilas A**, Gorgoulis VG. The single nucleotide polymorphism g.1548A >G (K469E) of the ICAM-1 gene is associated with worse prognosis in non-small cell lung cancer. *Tumour Biol*. 2012; 33(5):1429-36.
187. Talieri M, Zoma M, Devetzi M, **Scorilas A**, Ardavanis A. Kallikrein-related peptidase 6 (KLK6) gene expression in intracranial tumors. *Tumour Biol*. 2012; 33(5):1375-83.
188. Petraki C, Youssef YM, Dubinski W, Lichner Z, **Scorilas A**, Pasic MD, Komborozos V, Khalil B, Streutker C, Diamandis EP, Yousef GM. Evaluation and prognostic significance of human tissue kallikrein-related peptidase 10 (KLK10) in colorectal cancer. *Tumour Biol*. 2012; 33(4):1209-14.

189. Patsis C, Yiotakis I, **Scorilas A**. Diagnostic and prognostic significance of human kallikrein 11 (KLK11) mRNA expression levels in patients with laryngeal cancer. *Clin Biochem*. 2012; 45(9):623-30.
190. Evangelou I, Petraki C, Msaouel P, **Scorilas A**, Sdrolia E, Padazi G, Koborozos V, Koutsilieris M. Immunohistochemical expression of somatostatin receptor subtypes 2 and 5 in colorectal cancer. *Eur J Clin Invest*. 2012; 42(7):777-83.
191. Talieri M, Devetzi M, **Scorilas A**, Pappa E, Tsapralis N, Missitzis I, Ardavanis A. Human kallikrein-related peptidase 12 (KLK12) splice variants expression in breast cancer and their clinical impact. *Tumour Biol*. 2012; 33(4):1075-84.
192. Iakovlev VV, Gabril M, Dubinski W, **Scorilas A**, Youssef YM et al.. Microvascular density as an independent predictor of clinical outcome in renal cell carcinoma: an automated image analysis study. *Lab Invest*. 2012; 92(1):46-56.
193. Petraki C, Dubinski W, **Scorilas A**, Saleh C, Pasic MD, Kombozozos V, Khalil B, Gabril MY, Streutker C, Diamandis EP, Yousef GM. Evaluation and prognostic significance of human tissue kallikrein-related peptidase 6 (KLK6) in colorectal cancer. *Pathol Res Pract*. 2012; 208(2):104-8.
194. Korbakis D, **Scorilas A**. Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol. *Tumour Biol*. 2012; 33(3):865-75.
195. Avgeris M, Stravodimos K, **Scorilas A**. Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: Quantitative expression analysis and evaluation of its clinical significance. *Prostate*. 2011; 71(16):1780-9.
196. Talieri M, Alexopoulou DK, **Scorilas A**, Kypraios D, Arnogiannaki N, Devetzi M, Patsavela M, Xynopoulos D. Expression analysis and clinical evaluation of kallikrein-related peptidase 10 (KLK10) in colorectal cancer. *Tumour Biol*. 2011; 32(4):737-44.
197. Papageorgiou SG, Kontos CK, Pappa V, Thomadaki H, Kotsioti F, Dervenoulas J, Papageorgiou E, Economopoulos T, **Scorilas A**. The Novel Member of the BCL2 Gene Family, BCL2L12, Is Substantially Elevated in Chronic Lymphocytic Leukemia Patients, Supporting Its Value As a Significant Biomarker. *Oncologist*. 2011; 16(9):1280-91.
198. Dubinski W, Gabril M, Iakovlev VV, **Scorilas A**, Youssef YM et al. Assessment of the prognostic significance of endoglin (CD105) in clear cell renal cell carcinoma using automated image analysis. *Hum Pathol*. 2011; 43(7):1037-43.
199. Talieri M, Devetzi M, **Scorilas A**, Prezas P, Ardavanis A, Apostolaki A, Karameris A. Evaluation of kallikrein-related peptidase 5 expression and its significance for breast cancer

patients: association with kallikrein-related peptidase 7 expression. *Anticancer Res.* 2011; 31(9):3093-100.

200. Avgeris M, Papachristopoulou G, Polychronis A, **Scorilas A**. Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions. *Clin Proteomics.* 2011; 31,8(1):5.
201. Mathioudaki K, **Scorilas A**, Ardavanis A, Lymberi P, Tsiambas E, Devetzi M, Apostolaki A, Talieri M. Clinical evaluation of *PRMT1* gene expression in breast cancer. *Tumour Biol.* 2011; 32(3):575-82.
202. Jamaspishvili T, **Scorilas A**, Kral M, Khomeriki I, Kurfurstova D, Kolar Z, Bouchal J. Immunohistochemical localization and analysis of kallikrein-related peptidase 7 and 11 expression in paired cancer and benign foci in prostate cancer patients. *Neoplasma.* 2011; 58(4):298-303.
203. Xinopoulos D, Bassioukas SP, Kypreos D, Korkolis D, **Scorilas A**, Mavridis K, Dimitroulopoulos D, Paraskevas E. Pancreatic duct guidewire placement for biliary cannulation in a single-session therapeutic ERCP. *World J Gastroenterol.* 2011; 17(15):1989-95.
204. Fendri A, Kontos CK, Khabir A, Mokdad-Gargouri R, **Scorilas A**. *BCL2L12* is a Novel Biomarker for the Prediction of Short-term Relapse in Nasopharyngeal Carcinoma. *Mol Med.* 2011; 17(3-4):163-71.
205. Thomadaki H, Lymberopoulou-Karaliota A, Maniatakou A, **Scorilas A**. Synthesis, spectroscopic study and anticancer activity of a water-soluble Nb(V) peroxo complex. *J Inorg Biochem.* 2011; 105(2):155-63.
206. Dorn J, Harbeck N, Kates R, Gkazepis A, **Scorilas A**, Soosaipillai A, Diamandis E, Kiechle M, Schmalfeldt B, Schmitt M. Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. *Ann Oncol.* 2011; 22(4):877-83.
207. Papachristopoulou G, Avgeris M, Charlaftis A, **Scorilas A**. Quantitative expression analysis and study of the novel human kallikrein-related peptidase 14 gene (*KLK14*) in malignant and benign breast tissues. *Thromb Haemost.* 2011; 105(1):131-7.
208. Xinopoulos D, Kypreos D, Bassioukas SP, Korkolis D, Mavridis K, **Scorilas A**, Dimitroulopoulos D, Loukou A, Paraskevas E. Comparative study of balloon and metal olive dilators for endoscopic management of benign anastomotic rectal strictures: clinical and cost-effectiveness outcomes. *Surg Endosc.* 2010; 25(3):756-63.
209. Kontos CK, Papadopoulos IN, Fragoulis EG, **Scorilas A**. Quantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma. *Br J Cancer.* 2010; 102(9):1384-90.

210. Mavridis K, Avgeris M., Koutalellis G, Stravodimos K, **Scorilas A.** Expression analysis and study of the *KLK15* mRNA splice variants in prostate cancer and benign prostatic hyperplasia *Cancer Sci.* 2010; 101 (3):693 – 699.
211. Psyrris A, Papageorgiou S, Liakata E, **Scorilas A**, Rontogianni D, Kontos CK, Argyriou Pectasides D, Pappa V, Kolialexi A, Economopoulos T. Phosphatidylinositol 3'-kinase catalytic subunit {alpha} gene amplification contributes to the pathogenesis of mantle cell lymphoma. *Clin Cancer Res.* 2010; 391(4):467-74.
212. Mavridis K, Talieri M, **Scorilas A.** *KLK5* gene expression is severely upregulated in androgen independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone. *Biol Chem.* 2010; 391(4):467-74.
213. Florou D, Papadopoulos IN, **Scorilas A.** Molecular analysis and prognostic impact of the novel apoptotic gene *BCL2L12* in gastric cancer. *Biochem Biophys Res Commun.* 2010; 391(1):214-8.
214. Fendri A, Kontos CK, Khabir A, Mokdad-Gargouri R, Ardavanis A, **Scorilas A.** Quantitative analysis of *BCL2* mRNA expression in nasopharyngeal carcinoma: an unfavorable and independent prognostic factor. *Tumour Biol.* 2010; 31(5):391-9.
215. Konstantoudakis G, Florou D, Mavridis K, Papadopoulos IN, **Scorilas A.** Kallikrein-related peptidase 13 (*KLK13*) gene expressional status contributes significantly in the prognosis of primary gastric carcinomas. *Clin Biochem.* 2010; 43(15):1205-11.
216. Chow TF, Mankaruos M, **Scorilas A**, Youssef Y, Girgis A, Mossad S, Metias S, Rofael Y, Honey RJ, Stewart R, Pace KT, Yousef GM. The miR-17-92 Cluster is Over Expressed in and Has an Oncogenic Effect on Renal Cell Carcinoma. *J Urol.* 2010; 183(2):743-51.
217. Korbakis D, Gregorakis AK, **Scorilas A.** Quantitative analysis of human Kallikrein 5 (*KLK5*) expression in prostate needle biopsies: An independent cancer biomarker. *Clin Chem.* 2009; 55(5): 904-13.
218. Siu KW, DeSouza LV, **Scorilas A**, Romaschin AD, Honey RJ, Stewart R, Pace K, Youssef Y, Chow TF, Yousef GM. Differential protein expressions in renal cell carcinoma: new biomarker discovery by mass spectrometry. *J Proteome Res.* 2009; (8):3797-807.
219. Korbakis D, **Scorilas A.** Treatment of gastric cancer cells with 5-fluorouracil/leucovorin and irinotecan induces distinct alterations in the mRNA expression of the apoptosis-related genes, including the novel gene *BCL2L12*. *Tumour Biol.* 2009; 30(2):100-7.
220. Talieri M, Mathioudaki K, Prezas P, Alexopoulou DK, Diamandis EP, Xynopoulos D, Ardavanis A, Arnogiannaki N, **Scorilas A.** Clinical significance of kallikrein-related peptidase 7 (*KLK7*) in colorectal cancer. *Thromb Haemost.* 2009; 101(4):741-7.

221. Thomadaki H, Floros KV, **Scorilas A**. Molecular response of HL-60 cells to mitotic inhibitors vincristine and taxol visualized with apoptosis-related gene expressions, including the new member *BCL2L12*. *Ann N Y Acad Sci*. 2009; 1171:276-83.
222. Theophanous E, Petraki C, **Scorilas A**, Komborozos V, Veloudis G, Varga JL, Zarandi M, Schally AV, Koutsilieris M. The immunohistochemical expression of growth hormone-releasing hormone receptor splice variant 1 is a favorable prognostic marker in colorectal cancer. *Mol Med*. 2009; 15(7-8):242-7.
223. Emami N, **Scorilas A**, Soosaipillai A, Earle T, Mullen B, Diamandis EP. Association between kallikrein-related peptidases (KLKs) and macroscopic indicators of semen analysis: their relation to sperm motility. *Biol Chem*. 2009; 390(9):921-9.
224. Talieri M, Li L, Zheng Y, Alexopoulou DK, Soosaipillai A, **Scorilas A**, Xynopoulos D, Diamandis EP. The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. *Br J Cancer*. 2009; 100(10):1659-65.
225. Kountourakis P, Psyri A, **Scorilas A**, Markakis S, Kowalski D, Camp RL, Diamandis EP, Dimopoulos MA. Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. *Thromb Haemostasis*. 2009; 101(3):541-6.
226. Papachristopoulou G, Avgeris M, **Scorilas A**. Expression analysis and study of KLK4 in benign and malignant breast tumours. *Thromb Haemostasis*. 2009; 101 (2):381-7.
227. Thomadaki H, Mavridis K, Talieri M, **Scorilas A**. Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11. *Thromb Haemostasis*. 2009; 101(2):373-80.
228. Devetzi M, **Scorilas A**, Tsiambas E, Sameni M, Fotiou S, Sloane BF, Talieri M. Cathepsin B protein levels in endometrial cancer: Potential value as a tumour biomarker. *Gynecol Oncol*. 2009; 112(3):531-6.
229. Papadokostopoulou A, Mathioudaki K, **Scorilas A**, Xynopoulos D, Ardavanis A, Kouroumalis E, Talieri M. Colon cancer and protein arginine methyltransferase 1 gene expression. *Anticancer Res*. 2009; 29(4):1361-6.
230. Thomadaki H, **Scorilas A**. Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol. *Biol Chem*. 2008; 389(11):1427-34.
231. Kontos CK, Papadopoulos IN, **Scorilas A**. Quantitative expression analysis and prognostic significance of the novel apoptosis-related gene *BCL2L12* in colon cancer. *Biol Chem*. 2008; 389(12):1467-75.
232. Thomadaki H, Karaliota A, Litos C, **Scorilas A**. Enhanced

- concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu₂(L-carnitine)₂Cl₂(H₂O)₂]Cl₂, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines. *J Med Chem.* 2008; 51(13):3713-9.
233. Mathioudaki K, Papadokostopoulou A, **Scorilas A**, Xynopoulos D, Agnanti N, Talieri M. The PRMT1 gene expression pattern in colon cancer. *Br J Cancer.* 2008; 16,99(12):2094-9.
234. Kountourakis P, Psyrris A, **Scorilas A**, Camp R, Markakis S, Kowalski D, Diamandis EP, Dimopoulos MA. Prognostic value of kallikrein-related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA). *Cancer Sci.* 2008; 99(11):2224-9.
235. Ardavanis A, Koumna S, Fragos I, Malliou S, Kyriakou F, Mantzaris I, **Scorilas A**, Rigatos G. Erlotinib monotherapy in patients with advanced non-small cell lung cancer: an effective approach with low toxicity. *Anticancer Res.* 2008; 28(4C):2409-15.
236. Ardavanis A, Kountourakis P, Kyriakou F, Malliou S, Mantzaris I, Garoufali A, Yiotis I, **Scorilas A**, Baziotis N, Rigatos G. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer. *Oncologist.* 2008; 13 (4):361-9.
237. Psyrris A, Kountourakis P, **Scorilas A**, Markakis S, Camp R, Kowalski D, Diamandis EP, Dimopoulos MA. Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression. *Ann Oncol.* 2008; 19(7):1271-7,.
238. Avgeris M, Koutalellis G, Fragoulis EG, **Scorilas A**. Expression Analysis and Clinical Utility of L-Dopa Decarboxylase (*DDC*) in Prostate Cancer. *Clin Biochem.* 2008; 41(14-15):1140-9.
239. Thomadaki H, Tsiapalis CM, **Scorilas A**. The effect of the polyadenylation inhibitor cordycepin on human Molt-4 and Daudi leukaemia and lymphoma cell lines. *Cancer Chemother Pharmacol.* 2008; 61(4):703-11.
240. Gregorakis AK, Stefanakis S, Malovrouvas D, Petraki K, Gourgiotis D, **Scorilas A**. Total and free PSA kinetics in patients without prostate cancer undergoing radical cystoprostatectomy. *Prostate.* 2008; 68(7):759-65.
241. Pampalakis G, **Scorilas A**, Sotiropoulou G. Novel splice variants of prostate-specific antigen and applications in diagnosis of prostate cancer. *Clin Biochem.* 2008; 41(7-8):591-7.
242. Thomadaki H, **Scorilas A**, Tsiapalis CM, Havredaki M. The role of cordycepin in cancer treatment via induction or inhibition of apoptosis: implication of polyadenylation in a cell type specific manner. *Cancer Chemother Pharmacol.* 2008; 61(2):251-65.
243. Garoufali A, Kyriakou F, Kountourakis P, Yioti I, Malliou S,

- Nikaki A, Kardara E, Frangos I, Koumna S, Baziotis N, **Scorilas A**, Ardavanis A. Extracellular domain of HER2: a useful marker for the initial workup and follow-up of HER2-positive breast cancer. *J Buon*. 2008; 13(3):409-13.
244. Thomadaki H, **Scorilas A**. Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. *Ann N Y Acad Sci*. 2007; 1095:35-44.
245. Katsarou ME, Thomadaki H, Katsaros N and **Scorilas A**. Effect of bleomycin and cisplatin on the expression profile of SRA1, a novel member of pre-mRNA splicing factors, in HL-60 human promyelocytic leukemia cells. *Biol Chem*. 2007; 388(8):773-8.
246. Floros KV, Talieri M and **Scorilas A**. Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. *Biol Chem*. 2007; 387(12):1629-33.
247. Thomadaki H, Karaliota A, Litos C and **Scorilas A**. Enhanced Antileukemic Activity of the Novel Complex 2,5-Dihydroxybenzoate Molybdenum(VI) against 2,5-Dihydroxybenzoate, Polyoxometalate of Mo(VI), and Tetraphenylphosphonium in the Human HL-60 and K562 Leukemic Cell Lines. *J Med Chem*. 2007; 50(6):1316-21.
248. Floros KV, Thomadaki H, Florou D, Talieri M, **Scorilas A**. Alterations in mRNA expression of apoptosis-related genes BCL2, BAX, FAS, caspase-3, and the novel member BCL2L12 after treatment of human leukemic cell line HL60 with the antineoplastic agent etoposide. *Ann N Y Acad Sci*. 2007; 1090:89-97.
249. Zheng Y, Katsaros D, Shan SJ, de la Longrais IR, Porpiglia M, **Scorilas A**, Kim NW, Wolfert RL, Simon I, Li L, Feng Z, Diamandis EP. A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy. *Clin Cancer Res*. 2007; 13(23):6984-92.
250. Revelos K, Petraki C, **Scorilas A**, Stefanakis S, Malovrouvas D, Alevizopoulos N, Kanellis G, Halapas A, Koutsilieris M. Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. *Anticancer Res*. 2007; 27(5B):3651-60.
251. Simon I, Katsaros D, Rigault de la Longrais I, Massobrio M, **Scorilas A**, Kim NW, Sarno MJ, Wolfert RL, Diamandis EP. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. *Gynecol Oncol*. 2007; 106(2):334-41.
252. Dorn J, Schmitt M, Kates R, Schmalfeldt B, Kiechle M, **Scorilas A**, Diamandis EP, Harbeck N. Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian

- cancer patients. *Clin Cancer Res.* 2007; 13(6):1742-8.
253. Shan SJ, **Scorilas A**, Katsaros D, Diamandis EP. Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects. *Br J Cancer.* 2007; 96(2):362-72.
254. Efthimiadou EK, Thomadaki H, Sanakis Y, Raptopoulou CP, Katsaros N, **Scorilas A**, Karaliota A, Psomas G. Structure and biological properties of the copper(II) complex with the quinolone antibacterial drug N-propyl-norfloxacin and 2,2'-bipyridine. *J Inorg Biochem.* 2007; 101, 64-73.
255. Thomadaki H, Talieri M and **Scorilas A**. Prognostic value of the apoptosis related genes *BCL2* and *BCL2L12* in breast cancer. *Cancer Lett.* 2007; 247(1):48-55.
256. Prezas P, **Scorilas A**, Yfanti C, Viktorov P, Agnanti N, Diamandis E, Talieri M. The role of human tissue kallikreins 7 and 8 in intracranial malignancies. *Biol Chem.* 2006; 387(12) :1607-12.
257. Leoutsakou T, Talieri M and **Scorilas A**. Prognostic significance of the expression of SR-A1, encoding a novel SR-related CTD-associated factor, in breast cancer. *Biol Chem.* 2006; 387(12):1613-8.
258. Ardavanis A, **Scorilas A**, Tryfonopoulos D, et al.. Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results. *Oncologist.* 2006; 11(6):563-73.
259. Shan SJ, **Scorilas A**, Katsaros D, Rigault de la Longrais I, Massobrio M, Diamandis EP. Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols. *Clin Chem.* 2006; 52(10):1879-86.
260. Thomadaki H, Talieri M and **Scorilas A**. Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes *BCL2*, *BCL2L12*, *BAX*, *CASPASE-9* and *FAS*. *Biol Chem.* 2006; 387(8):1081-6.
261. Leoutsakou T, Talieri M and **Scorilas A**. Expression analysis and prognostic significance of the SRA1 gene, in ovarian cancer. *Biochem Biophys Res Commun.* 2006; 344(2):667-74.
262. Agiamarnioti K, Triantis T, Papadopoulos K and **Scorilas A**. 10-(2-Biotinyloxyethyl)-9-acridone. A novel fluorescent label for (strept)avidin-biotin based assays. *J Photochem Photobiol A.* 2006; 181:126-131.
263. **Scorilas A** and Gregorakis AK. mRNA expression analysis of human kallikrein 11 (*KLK11*) may be useful in the discrimination of benign prostatic hyperplasia from prostate cancer after needle prostate biopsy. *Biol Chem.* 2006; 387(6):789-93.
264. Thomadaki H, Tsiapalis CM and **Scorilas A**. Polyadenylate polymerase modulations in human epithelioid cervix and breast cancer cell lines, treated with etoposide or cordycepin, follow cell cycle rather than apoptosis induction. *Biol Chem.* 2006;

386(5):471-80.

265. Slagter MH, **Scorilas A**, Gooren LJ, de Ronde W, Soosaipillai A, Giltay EJ, Paliouras M, Diamandis EP. Effect of Testosterone Administration on Serum and Urine Kallikrein Concentrations in Female-to-Male Transsexuals. *Clin Chem*. 2006; 52(8):1546-51.
266. Borgono CA, Kishi T, **Scorilas A**, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, Diamandis EP. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer. *Clin Cancer Res*. 2006; 12: 1487-1493.
267. Slagter MH, Gooren LJ, de Ronde W, Soosaipillai A, **Scorilas A**, Giltay EJ, Paliouras M, Diamandis EP. Serum and Urine Tissue Kallikrein Concentrations in Male-to-Female Transsexuals Treated with Antiandrogens and Estrogens. *Clin Chem*. 2006; 52:1356-1365.
268. Slagter MH, Gooren LJ, **Scorilas A**, Petraki CD, Diamandis EP. Effects of Long-term Androgen Administration on Breast Tissue of Female-to-Male Transsexuals. *J Histochem Cytochem*. 2006; 54: 905-910.
269. Oikonomopoulou K, **Scorilas A**, Michael IP, Grass L, Soosaipillai A, Rosen B, Murphy J, Diamandis EP. Kallikreins as markers of disseminated tumour cells in ovarian cancer-- a pilot study. *Tumour Biol*. 2006; 27(2):104-14.
270. Stavropoulou P, Gregorakis AK, Plebani M and **Scorilas A**. Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer. *Clin Chim Acta*. 2005; 357:190-5.
271. **Scorilas A**, Agiamarnioti K, Papadopoulos K. Novel biotinylated acridinium derivatives: new reagents for fluorescence immunoassays and proteomics. *Clin Chim Acta*. 2005; 357:159-67.
272. Katsarou ME, Papakyriakou A, Katsaros N and **Scorilas A**. Expression of the C-terminal domain of novel human SR-A1 protein: interaction with the CTD domain of RNA polymerase II. *Biochem Biophys Res Commun*. 2005; 334:61-8.
273. Yannopoulos A, Dimitriadis E, **Scorilas A**, Trangas T, Markakis E, Talieri M. mRNA quantification and clinical evaluation of telomerase reverse transcriptase subunit (*hTERT*) in intracranial tumours of patients in the island of Crete. *Br J Cancer*. 2005; 93:152-8.
274. Gregorakis AK, Malovrouvas D, Stefanakis S, Petraki K and **Scorilas A**. Free/Total PSA (F/T ratio) kinetics in patients with clinically localized prostate cancer undergoing radical prostatectomy. *Clin Chim Acta*. 2005; 357:196-201.
275. Revelos K, Petraki C, Gregorakis A, **Scorilas A**, Papanastasiou P, Tenta R, Koutsilieris M. p27(kip1) and ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer. *In Vivo*. 2005; 19:911-20.
276. Ardavanis A, Tryfonopoulos D, Orfanos G, Karamouzis M,

- Scorilas A, Alexopoulos A, Rigatos G. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series. *Onkologie*. 2005; 28(11):558-64.
277. Revelos K, Petraki C, Gregorakis A, **Scorilas A**, Papanastasiou P, Koutsilieris M. Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. *Anticancer Res*. 2005; 25:3123-33.
278. **Scorilas A**, Borgono CA, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, Diamandis EP. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. *J Clin Oncol*. 2004; 22:678-85.
279. Floros KV, Thomadaki H, Katsaros N, Talieri M and **Scorilas A**. mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the *BCL2*-family, *BCL2L12*, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. *Biol Chem*. 2004; 385(11):1099-103.
280. Mathioudaki K, Leotsakou T, Papadokostopoulou A, Paraskevas E, Ardavanis A, Talieri M and **Scorilas A**. *SR-A1*, a member of the human pre-mRNA splicing factor family, and its expression in colon cancer progression. *Biol Chem*. 2004; 385(9):785-90.
281. Diamandis EP, Borgono CA, **Scorilas A**, Harbeck N, Dorn J, Schmitt M. Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients. *Clin Biochem*. 2004; 37(9):823-9.
282. Talieri M, Diamandis EP, Gourgiotis D, Mathioudaki K, **Scorilas A**. Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma. *Thromb Haemost*. 2004; 91:180-6.
283. Diamandis EP, **Scorilas A**, Kishi T, Blennow K, Luo LY, Soosaipillai A, Rademaker AW, Sjogren M. Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. *Clin Biochem*. 2004; 7:230-7.
284. Talieri M, Papadopoulou S, **Scorilas A**, Xynopoulos D, Arnogianaki N, Plataniotis G, Yotis J, Agnanti N. Cathepsin B and cathepsin D expression in the progression of colorectal adenoma to carcinoma. *Cancer Lett*. 2004; 205:97-106.
285. Mathioudaki K, **Scorilas A**, Papadokostopoulou A, Xynopoulos D, Arnogianaki N, Agnanti N, Talieri M. Expression analysis of *BCL2L12*, a new member of apoptosis-related genes, in colon cancer. *Biol Chem*. 2004; 385(9):779-83.
286. Stephan C, Yousef GM, **Scorilas A**, Jung K, Jung M, Kristiansen G, Hauptmann S, Kishi T, Nakamura T, Loening SA, Diamandis EP. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. *J Urol*.

2004; 171,187-91.

287. **Scorilas A**, Plebani M, Mazza S, Basso D, Soosaipillai AR, Katsaros D, Pagano F, Diamandis EP. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. *Prostate*. 2003; 54:220-229.
288. **Scorilas A**, Chiang PM, Katsaros D, Yousef GM, Diamandis EP. Molecular characterization of a new gene, CEAL1, encoding for a carcinoembryonic antigen-like protein with a highly conserved domain of eukaryotic translation initiation factors. *Gene*. 2003; 310:79-89.
289. Floros KV, Thomadaki H, Lallas G, Katsaros N, Talieri M, **Scorilas A**. Cisplatin-induced apoptosis in HL-60 human promyelocytic leukemia cells: differential expression of BCL2 and novel apoptosis-related gene BCL2L12. *Ann N Y Acad Sci*. 2003; 1010,153-8.
290. Diamandis EP, Borgono CA, **Scorilas A**, Yousef GM, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M. Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis. *Tumour Biol*. 2003; 24,299-309.
291. Talieri M, Diamandis EP, Katsaros N, Gourgiotis D, **Scorilas A**. Expression of BCL2L12, a new member of apoptosis-related genes, in breast tumors. *Thromb Haemost*. 2003; 89:1081-8.
292. Stephan C, Yousef GM, **Scorilas A**, Jung K, Jung M, Kristiansen G, Hauptmann S, Bharaj BS, Nakamura T, Loening SA, Diamandis EP. Quantitative analysis of kallikrein 15 gene expression in prostatic tissue. *J Urol*. 2003; 169:361-364.
293. Nakamura T, **Scorilas A**, Stephan C, Jung K, Soosaipillai AR, Diamandis EP. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. *Cancer Res*, 2003; 63:6543-6546.
294. Yousef GM, **Scorilas A**, Katsaros D, Fracchioli S, Iskander L, Borgono C, Puopolo M, Massobrio M, Diamandis EP. Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. *J Clin Oncol*. 2003; 21:3119-3126.
295. Yousef GM, Polymeris ME, Grass L, Soosaipillai A, Chan PC, **Scorilas A**, Borgono C, Harbeck N, Schmalfeldt B, Dorn J, Schmitt M, Diamandis EP. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. *Cancer Res*. 2003; 63:3958-3965.
296. Yousef GM, Stephan C, **Scorilas A**, Ellatif MA, Jung K, Kristiansen G, Jung M, Polymeris ME, Diamandis EP. Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. *Prostate*. 2003; 56:287-292.
297. Borgono CA, Fracchioli S, Yousef GM, Luo LY, Soosaipillai A,

- Puopolo M, Grass L, **Scorilas A**, Diamandis EP, Katsaros D. Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma. *Int J Cancer*. 2003; 106:605-610.
298. Kishi T, Grass L, Soosaipillai A, **Scorilas A**, Harbeck N, Schmalfeldt B, Dorn J, Mysliwiec M, Schmitt M, Diamandis EP. Human kallikrein 8, a novel biomarker for ovarian carcinoma. *Cancer Res*. 2003; 63:2771-2774.
299. Nakamura T, Stephan C, **Scorilas A**, Yousef GM, Jung K, Diamandis EP. Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues. *Urology*. 2003; 61:1042-1046.
300. Yousef GM, Polymeris ME, Yacoub GM, **Scorilas A**, Soosaipillai A, Popalis C, Fracchioli S, Katsaros D, Diamandis EP. Parallel overexpression of seven kallikrein genes in ovarian cancer. *Cancer Res*. 2003; 63:2223-2227.
301. Yousef GM, Scorilas A, Nakamura T, Ellatif MA, Ponzzone R, Biglia N, Maggiorotto F, Roagna R, Sismondi P, Diamandis EP. The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer. *Breast Cancer Res Treat*. 2003; 78:149-158.
302. Nakamura T, Scorilas A, Stephan C, Yousef GM, Kristiansen G, Jung K, Diamandis EP. Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. *Br J Cancer*. 2003; 88:1101-1104.
303. Diamandis EP, **Scorilas A**, Katsaros N, Stenman C, Henrik A, Soosaipillai A, Grass L, Katsaros D. Human kallikrein 6 (hK6): A new serum biomarker for diagnosis and prognosis of ovarian carcinoma. *J Clin Oncol*. 2003; 21:1035-1043.
304. Luo Y, Katsaros D, Scorilas A, Fracchioli S, Bellino R, Gramberen M, Bruijn H, Henrik A, Stenman U, Massobrio M, Zee A, Vergote I, Diamandis EP. The Diagnostic and Prognostic Value of Serum Human Kallikrein 10 in Ovarian Cancer. *Cancer Res*. 2003; 63:807-811.
305. Kyriakopoulou L, Yousef GM, **Scorilas A**, Katsaros D, Massobrio M, Fracchioli S, Diamandis EP. Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. *Clin Biochem*. 2003; 36:135-143.
306. Yousef GM, Fracchioli S, **Scorilas A**, Borgoño C, Iskander L, Richiardi G, Massobrio M, Katsaros D, Diamandis EP. Steroid hormone regulation and prognostic value of the human Kallikrein gene 14 (KLK14) in ovarian cancer. *Am J Clin Pathol*. 2003; 119:346-355.
307. **Scorilas A**, Levesque AL, Ashworth KL, Diamandis E.P. Cloning, structural characterization, physical mapping and expression pattern of the human alpha-adaptin A gene. *Gene*. 2002; 289: 191-199.
308. **Scorilas A**, Fotiou S, Tsiambas E, Yotis J, Kotsiandri F, Sameni M, Sloane BF, Talieri M. Determination of Cathepsin B expression

may offer additional prognostic information for ovarian cancer patients. *Biol Chem.* 2002; 383:1297 – 1303.

309. **Scorilas A**, Magklara A, Hoffman BR, Bromberg RM, Bjartell A and Diamandis EP. Highly sensitive array analysis using time resolved fluorescence and a novel streptavidin-based reagent. *Anal Sci.* 2002; 17:547-550.
310. Yousef GM, **Scorilas A**, Magklara A, Memari N, Ponzzone R, Sismondi P, Biglia N, Abd Ellatif M, Diamandis EP. The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. *Br J Cancer.* 2002; 87:1294-3000.
311. Yousef GM, Borgono CA, **Scorilas A**, Ponzzone R, Biglia N, Iskander L, Polymeris ME, Roagna R, Sismondi P, Diamandis EP. Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis. *Br J Cancer.* 2002; 87:1287-1293.
312. Yousef GM, Obiezu CV, Jung K, Stephan C, **Scorilas A**, Diamandis EP. Differential expression of Kallikrein gene 5 in cancerous and normal testicular tissues. *Urology.* 2002; 60:714-718.
313. Zarghooni M, Soosaipillai A, Grass L, **Scorilas A**, Mirazimi N, Diamandis EP. Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients. *Clin Biochem* 2002; 3:225-231.
314. Chang A, Yousef GM, **Scorilas A**, Grass L, Sismondi P, Ponzzone R, Diamandis EP. Human Kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: An independent indicator of favorable prognosis in breast cancer. *Br J Cancer.* 2002; 86:1457-1464.
315. Hoffman BR, Katsaros D, **Scorilas A**, Diamandis P, Fracchioli S, Longrais IA, Colgan T, Puopolo M, Giardina G, Massobrio M, Diamandis EP. Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. *Br J Cancer.* 2002; 23:763-771.
316. Obiezu CV, Soosaipillai A, Jung K, Stephan C, **Scorilas A**, Howarth DH, Diamandis EP. Detection of human Kallikrein 4 (hK4) in normal and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. *Clin Chem.* 2002; 48:1232-1240.
317. Yousef GM, **Scorilas A**, Kyriakopoulou LG, Rendl L, Diamandis M, Ponzzone R, Biglia N, Giai M, Roagna R, Sismondi P, Diamandis EP. Human Kallikrein Gene 5 (KLK5) Expression by Quantitative PCR: An Independent Indicator of Poor Prognosis in Breast Cancer. *Clin Chem* 2002; 48:1241-1250.
318. Yousef GM, **Scorilas A**, Chang A, Rendl L, Diamandis M, Jung K, Diamandis EP. Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. *Prostate.* 2002; 51:126-132.

319. Papadopoulou S, **Scorilas A**, Yotis J, Arnogiannaki N, Plataniotis G, Agnanti N. Significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas. *Tumour Biol.* 2002; 23:170-178.
320. **Scorilas A**, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P, Trangas T, Talieri M. Overexpression of matrix - metalloproteinase-9 in human breast cancer. A new favorable indicator in node-negative patients. *Br J Cancer.* 2001; 84:1488-1496.
321. **Scorilas A**, Kyriakopoulou L, Yousef GM, Ashworth L, Kwamie A, Diamandis E.P. Molecular cloning, physical mapping and expression analysis of a novel gene, BCL2L12, encoding for a proline-rich protein with a highly conserved BH2 domain of the Bcl-2 family. *Genomics.* 2001; 72: 217-221.
322. **Scorilas A**, Bharaj B, Gai M and Diamandis EP. Codon 89 polymorphism in the human 5 α reductase gene in primary breast cancer. *Br J Cancer.* 2001; 84:760-767.
323. **Scorilas A**, Yousef GM, Jung K, Meyts E, Carsten S, Diamandis EP. Identification and characterization of a novel human testis specific kinase substrate gene which is down-regulated in testicular carcinomas. *Biochem Biophys Res Commun.* 2001; 285: 400-408.
324. **Scorilas A**, Kyriakopoulou L, Katsaros D and Diamandis EP. Cloning of a gene (SR-A1), encoding for a new member of the human Ser/Arg-rich family of Pre-mRNA splicing factors: Overexpression in aggressive ovarian cancer. *Br J Cancer.* 2001; 85: 190-198.
325. Obiezu CV, **Scorilas A**, Magklara A, Thornton MH, Wang CY, Stanczyk FZ, Diamandis EP. Prostate specific antigen (PSA) and human glandular kallikrein (hK2) are markedly elevated in polycystic ovary syndrome. *J Clin Endocr Metab.* 2001; 86:1558-1561.
326. Khosravi J, Diamandi A, Mistry J, **Scorilas A**. Insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 in benign prostatic hyperplasia and prostate cancer. *J Clin Endocr Metab.* 2001; 86:694-699.
327. Kim H, **Scorilas A**, Katsaros D, Yousef GM, Massobrio M, Fracchioli S, Piccinno R, Gordini G, Diamandis EP. Human Kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. *Br J Cancer.* 2001; 84:643-650.
328. Magklara A, **Scorilas A**, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Danese S, Diamandis EP. The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. *Clin Cancer Res.* 2001; 7:806-811.
329. Luo LY, Bunting P, **Scorilas A**, Diamandis EP. Human kallikrein 10: A novel tumor marker for ovarian carcinoma? *Clin*

Chim Acta. 2001; 306:111-118.

330. Obiezu CV, **Scorilas A**, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Rigault de la Longrais IA, Arisio R, Diamandis EP. Higher kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. *Clin Cancer Res.* 2001; 7: 2380-2386.
331. Luo LY, Katsaros D, **Scorilas A**, Fracchioli S, Piccinno R, Rigault de la Longrais IA, Howarth DJ, Diamandis EP. Prognostic Value of Human Kallikrein 10 Expression in Epithelial Ovarian Carcinoma. *Clin Cancer Res.* 2001; 7: 2372-2379.
332. Yousef GM, **Scorilas A**, Jung K, Aschworth L and Diamandis EP. Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer. *J Biol Chem.* 2001; 276:53-61.
333. Papadopoulou S, **Scorilas A**, Arnogianaki N, Yotis J, Papapanayiotou B, Agnantis N, Talieri M. Expression of gelatinase-A (MMP-2) in human colon cancer and normal colon mucosa *Tumour Biol.* 2001; 22: 383-289.
334. Yousef GM, Kyriakopoulou LG, **Scorilas A**, Fracchioli S, Ghiringhello B, Zarghooni M, Chang A, Diamandis M, Giardina G, Hartwick WJ, Richiardi G, Massobrio M, Diamandis EP, Katsaros D. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. *Cancer Res.* 2001; 61:7811-7818.
335. Kalomenidis I, Orphanidou D, Papamichalis G, Vassilakopoulos T, **Skorilas A**, Rasidakis A, Papastamatiou H, Jordanoglou J, Roussos C. Combined expression of p53, Bcl-2, and p21WAF-1 proteins in lung cancer and premalignant lesions: association with clinical characteristics. *Lung.* 2001; 179: 265-278.
336. **Scorilas A**, Talieri M, Ardavanis A, Curtis N, Yotis J, Dimitriadis E, Tsiapalis C and TrangasT. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer. *Cancer Res.* 2000; 60:5427-5433.
337. **Scorilas A**, Bjartell A, Lilja H, Moller C, Diamandis EP. Streptavidin-polyvinylamine conjugates labeled with a europium chelate: Applications in immunoassay, immunohistochemistry and microarrays. *Clin Chem.* 2000; 46: 1450-1455.
338. **Scorilas A**, Black MH, Talieri M, Diamandis EP. Genomic organization of the human protein arginine methyltransferase 1 gene (PRMT1): Differential expression of splice variants in breast cancer *Biochem Biophys Res Commun.* 2000; 278:349-259.
339. **Scorilas A** and Diamandis EP. Polyvinylamine-streptavidin complexes labeled with a europium chelator - A universal detection reagent for solid-phase time resolved fluorometric applications. *Clin Biochem.* 2000; 33: 345-350.
340. **Scorilas A**, Yu H, Soosaipilai A, Gregorakis A and Diamandis EP. Comparison of the percent free prostate-specific antigen levels

in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy. *Clin Chim Acta*. 2000; 292: 127-138.

341. Yousef GM, **Scorilas A** and Diamandis EP. Genomic organization, mapping, tissue expression and hormonal regulation of trypsin-like serine protease (TLSP PRSS20), a new member of the human kallikrein gene family. *Genomics*. 2000; 63: 88-96.
342. Yousef GM, **Scorilas A**, Magklara A, Soosaipillai A and Diamandis E.P. The KLK7 (PRSS6) gene, encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family - genomic characterization, mapping, tissue expression and hormonal regulation. *Gene*. 2000; 254:119-128.
343. Bharaj B, **Scorilas A**, Giai M and Diamandis EP. TA Repeat Polymorphism of the 5 α -Reductase Gene and Breast Cancer. *Cancer Epidem Biomar*. 2000; 6:387-393.
344. Nam R, Diamandis EP, Toi A, Trachtenberg J, Magklara A, **Scorilas A**, Papanastasiou P, Soosaipillai A, Jewett M and Narod S. Serum human glandular kallikrein (hK2) levels predict the presence of prostate cancer among men with moderately elevated prostate specific-antigen. *J Clin Oncol*. 2000; 5: 1036-1042.
345. Sklavounou A, Chrysomali E, **Scorilas A**, Karameris A. TNF- α expression and apoptosis-regulating proteins in oral lichen planus: a comparative immunohistochemical evaluation. *J Oral Pathol Med*. 2000; 29: 370-375.
346. Bharaj B, **Scorilas A**, Diamandis EP, Giai M, Levesque MA, Sutherland DJ, Hoffman BR. Breast cancer prognostic significance of a single nucleotide polymorphism in the proximal androgen response element of the prostate specific antigen gene promoter. *Breast Cancer Res Treat*. 2000; 61:111-119.
347. Obiezu CV, Giltay EJ, Magklara A, **Scorilas A**, Gooren LJ, Yu H, Howarth DJ, Diamandis EP. Dramatic suppression of serum prostate specific antigen and human glandular kallikrein by anti-androgens in male to female transsexuals. *J Urol*. 2000; 163:802-805.
348. Obiezu C, Giltay E, Magklara A, **Scorilas A**, Yu H, Gooren L and Diamandis EP. Serum prostate specific antigen is significantly elevated after testosterone administration in female to male transsexuals. *Clin Chem*. 2000; 46:859-862.
349. Magklara A, **Scorilas A**, Stephan C, Kristiansen G, Hauptmann S, Jung K, Diamandis EP. Decreased concentrations of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) in malignant vs non-malignant prostatic tissue. *Urology*. 2000; 56:527-532.
350. Yousef GM, Chang A, **Scorilas A**, Eleftherios P. Diamandis. Genomic organization of the human kallikrein locus on chromosome 19q13.3-q13.4. *Biochem Biophys Res Commun*.

2000; 276: 125-133.

351. **Scorilas A**, Trangas T, Yotis J, Pateras C, Talieri M. Determination of c-myc amplification and overexpression in breast cancer patients. Evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathologic characteristics using univariate and multivariate analysis. *Br J Cancer*. 1999; 81:1385-1391.
352. **Scorilas A**, Diamandis EP, Levesque MA, Papanistasiou-Diamandi A, Khosravi MJ, Giai M, Ponzzone R, Roagna R, Sismondi P and Lopez-Otin C. Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: an independent favorable prognostic factor in node-positive patients. *Clin Cancer Res*. 1999; 5:1778-1785.
353. **Scorilas A**, Yotis I, Pateras CH, Trangas T, Talieri M. Predictive value c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis. *Clin Cancer Res*. 1999; 5:815-821.
354. Magklara A, **Scorilas A**, Catalona WJ, Diamandis EP. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. *Clin Chem*. 1999; 45:1960-1966.
355. Magklara A, **Scorilas A**, Lopez-Otin C, Vizoso F, Ruibal A, Diamandis EP. Human glandular kallikrein (hK2) in breast milk, amniotic fluid and breast cyst fluid. *Clin Chem*. 1999; 45:1774-1780.
356. **Scorilas A**, Curtis N, Yotis J, Talieri M, Michailakis M, Trangas T. Poly(A)polymerase activity levels in breast tumor cytosols. *J Exp Clin Canc Res*. 1998; 17:511-518.
357. Ardavanis A, **Scorilas A**, Loukeri A, Gerakini F, Pissakas G, Missitzis I, Apostolikas N, Yiotis I. Cathepsin D may help in discriminating node-negative breast cancer patients at risk for local-regional recurrence. *Anticancer Res*. 1998; 18: 2885-2890.
358. Ardavanis A, Gerakini F, Amanatidou A, **Scorilas A**, Pateras C, Garoufali A, Pissakas G, Stravolemos K, Apostolikas N, Yiotis I. Relationships between cathepsin-D, pS2 protein and hormonal receptors in breast cancer cytosols: Inconsistency with their established prognostic significance. *Anticancer Res*. 1997; 17: 3665-3670.
359. Ardavanis A, **Scorilas A**, Amanatidou A, Gerakini F, Missitzis I, Garoufali A, Pissakas G, Pateras C, Apostolikas N, Rigatos G and Yiotis I. Cathepsin-D concentration in tumour cytosols improves the accuracy of prognostic evaluation of primary breast cancer. *Anticancer Res*. 1997; 17: 1405-1410.
360. **Scorilas A**, Yotis I, Stravolemos K, Gouriotis D, Keramopoulos A, Ampela K, Talieri M, Trangas T. c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer

patients. *Anticancer Res.* 1995; 15: 1543-1548.

361. **Scorilas A**, Yotis I, Gouriotis D, Keramopoulos A, Ampela K, Trangas T, Talieri M. Cathepsin-D and c-erbB-2 have an additive prognostic value for breast cancer patients. *Anticancer Res.* 1993; 13: 1895-1900.

Reviews

362. Boti MA, Athanasopoulou K, Adamopoulos PG, Sideris DC, **Scorilas A**. Recent Advances in Genome-Engineering Strategies. *Genes (Basel)*. 2023 Jan 2;14(1):129.
363. Adamopoulos PG, Athanasopoulou K, Daneva GN, **Scorilas A**. The Repertoire of RNA Modifications Orchestrates a Plethora of Cellular Responses. *Int J Mol Sci.* 2023 Jan 25;24(3):2387.
364. Athanasopoulou K, Daneva GN, Boti MA, Dimitroulis G, Adamopoulos PG, **Scorilas A**. The Transition from Cancer "omics" to "epi-omics" through Next- and Third-Generation Sequencing. *Life (Basel)*. 2022 Dec 2;12(12):2010.
365. Papadimitriou MA, Panoutsopoulou K, Pilala KM, **Scorilas A**, Avgeris M. Epi-miRNAs: Modern mediators of methylation status in human cancers. *Wiley Interdiscip Rev RNA.* 2022 May 17:e1735.
366. Trougakos IP, Terpos E, Alexopoulos H, Politou M, Paraskevis D, **Scorilas A**, Kastritis E, Andreacos E, Dimopoulos MA. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. *Trends Mol Med.* 2022 Jul;28(7):542-554.
367. Athanasopoulou K, Boti MA, Adamopoulos PG, Skourou PC, **Scorilas A**. Third-Generation Sequencing: The Spearhead towards the Radical Transformation of Modern Genomics. *Life (Basel)*. 2021; 12(1):30.
368. Papatsirou M, Artemaki PI, Karousi P, **Scorilas A**, Kontos CK. Circular RNAs: Emerging Regulators of the Major Signaling Pathways Involved in Cancer Progression. *Cancers (Basel)*. 2021; 13(11):2744.
369. Artemaki PI, Letsos PA, Zoupa IC, Katsaraki K, Karousi P, Papageorgiou SG, Pappa V, **Scorilas A**, Kontos CK. The Multifaceted Role and Utility of MicroRNAs in Indolent B-Cell Non-Hodgkin Lymphomas. *Biomedicines.* 2021; 9(4):333.
370. Papanota AM, Karousi P, Kontos CK, Ntanas-Stathopoulos I, **Scorilas A**, Terpos E. Multiple Myeloma Bone Disease: Implication of MicroRNAs in Its Molecular Background. *Int J Mol Sci.* 2021; 22(5):2375.
371. Katsaraki K, Karousi P, Artemaki PI, **Scorilas A**, Pappa V, Kontos CK, Papageorgiou SG. MicroRNAs: Tiny Regulators of Gene Expression with Pivotal Roles in Normal B-Cell Development and B-Cell Chronic

- Lymphocytic Leukemia. *Cancers (Basel)*. 2021; 13(4):593.
372. Alygizakis N, Markou AN, Rousis NI, Galani A, Avgeris M, Adamopoulos PG, **Scorilas A**, Lianidou ES, Paraskevis D, Tsiodras S, Tsakris A, Dimopoulos MA, Thomaidis NS. Analytical methodologies for the detection of SARS-CoV-2 in wastewater: Protocols and future perspectives. *Trends Analyt Chem*. 2021; 134:116125.
373. Papatsirou M, Artemaki PI, **Scorilas A**, Kontos CK. The role of circular RNAs in therapy resistance of patients with solid tumors. *Per Med*. 2020;17(6):469-490.
374. Artemaki PI, **Scorilas A**, Kontos CK. Circular RNAs: A New Piece in the Colorectal Cancer Puzzle. *Cancers (Basel)*. 2020; 12(9):2464.
375. Tolios A, De Las Rivas J, Hovig E, Trouillas P, **Scorilas A**, Mohr T. Computational approaches in cancer multidrug resistance research: Identification of potential biomarkers, drug targets and drug-target interactions. *Drug Resist Updat*. 2020 Jan; 48:100662.
376. Sarmiento-Ribeiro AB, **Scorilas A**, Gonçalves AC, Efferth T, Trougakos IP. The emergence of drug resistance to targeted cancer therapies: Clinical evidence. *Drug Resist Updat*. 2019 Dec;47:100646.
377. Panoutsopoulou K, Avgeris M, **Scorilas A**. miRNA and long non-coding RNA: molecular function and clinical value in breast and ovarian cancers. *Expert Rev Mol Diagn*. 2018; 18(11):963-979.
378. Adamopoulos PG, Tsiakanikas P, **Scorilas A**. Kallikrein-related peptidases and associated microRNAs as promising prognostic biomarkers in gastrointestinal malignancies. *Biol Chem*. 2018; 399(8):821-836.
379. Avgeris M, **Scorilas A**. Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies. *Expert Opin Ther Tar*. 2016; 20(7):801-18.
380. Christodoulou MI, Scorilas A. Metformin and anti-cancer therapeutics: hopes for a more enhanced armamentarium against human neoplasias? *Curr Med Chem*. 2016; 24(1):14-56.
381. Kontos CK, Adamopoulos PG, Scorilas A. Prognostic and predictive biomarkers in prostate cancer. *Expert Rev Mol Diagn*. 2015; 15(12):1567-76.
382. Kladi-Skandali A, Michaelidou K, Scorilas A, Mavridis K. Long Noncoding RNAs in Digestive System Malignancies: A Novel Class of Cancer Biomarkers and Therapeutic Targets? *Gastroenterol Res Pract*; 2015:319861.
383. **Scorilas A.**, Mavridis K. Predictions for the future of kallikrein-related peptidases in molecular diagnostics. *Expert Rev Mol Diagn*. 2014; 14(6):713-22.
384. Mavridis K, Avgeris M, **Scorilas A**. Targeting kallikrein-related peptidases in prostate cancer. *Expert Opin Ther Tar*. 2014;

18(4):365-83.

385. Schmitt M, Magdolen V, Yang F, Kiechle M, Bayani J, Yousef GM, **Scorilas A**, Diamandis EP, Dorn J. Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies. *Radiol Oncol*. 2013; 47(4):319-29.
386. Christodoulou MI, Kontos CK, Halabalaki M, Skaltsounis AL, **Scorilas A**. Nature Promises New Anticancer Agents: Interplay with the Apoptosis-related BCL2 Gene Family. *Anticancer Agents Med Chem*. 2013; 14(3):375-99.
387. Kontos CK, **Scorilas A**, Papavassiliou AG. The role of transcription factors in laboratory medicine. *Clin Chem Lab Med*. 2013; 51(8):1563-71.
388. Kontos CK, Christodoulou MI, **Scorilas A**. Apoptosis-related BCL2-family members: key players in chemotherapy. *Anticancer Agents Med Chem*. 2013; 14(3):353-74.
389. Kontos CK, Mavridis K, Talieri M, **Scorilas A**. Kallikrein-related peptidases (KLKs) in gastrointestinal cancer: Mechanistic and clinical aspects. *Thromb Haemost*. 2013; 110(3):450-7.
390. Kontos CK, **Scorilas A**. Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers. *Clin Chem Lab Med*. 2012; 50(11):1877-91.
391. Avgeris M, Mavridis K, **Scorilas A**. Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. *Biol Chem*. 2012; 393(5):301-17.
392. Tzifi F, Economopoulou C, Gourgiotis D, Ardavanis A, Papageorgiou S, **Scorilas A**. The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias. *Adv Hematol*. 2012; 2012:524308.
393. Avgeris M, Mavridis K, **Scorilas A**. Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. *Biol Chem*. 2010; 391(5):505-11.
394. Mavridis K and **Scorilas A**. Prognostic value and biological role of the kallikrein-related peptidases in human malignancies. *Future Oncol*. 2010; 6(2):269-85.
395. Thomadaki H, **Scorilas A**. Molecular profile of the BCL2 family of the apoptosis related genes in breast cancer cells after treatment with cytotoxic/cytostatic drugs. *Connect Tissue Res*. 2008; 49(3):261-4.
396. Thomadaki H and **Scorilas A**. BCL2 Family of apoptosis - related genes: Functions and clinical implications in cancer. *Crit Rev Cl Lab Sci*. 2006; 42:1-67.
397. Lundwall A, Band V, Blaber M, Clements JA, Courty Y, Diamandis EP, Fritz H, Lilja H, Malm J, Maltais LJ, Olsson AY, Petraki C, **Scorilas A**, Sotiropoulou G, Stenman UH, Stephan C,

Talieri M, Yousef GM. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. *Biol Chem.* 2006; 387(6):637-41.

398. Yousef GM, Obiezu CV, Luo LY, Magklara A, Borgono CA, Kishi T, Memari N, Michael P, Sidiropoulos M, Kurlender L, Economopolou K, Kapadia C, Komatsu N, Petraki C, Elliott M, **Scorilas A**, Katsaros D, Levesque MA, Diamandis EP. Human tissue kallikreins: from gene structure to function and clinical applications. *Adv Clin Chem.* 2005; 39:11-79.
399. **Scorilas A**. Polyadenylate polymerase (PAP) and 3' end pre-mRNA processing: Function, assays and association to disease. *Crit Rev Cl Lab Sci.* 2002; 39:193-224.

Editorials

400. Avgeris M, Marmarinos A, Gourgiotis D, **Scorilas A**. Jagged Ends of Cell-Free DNA: Rebranding Fragmentomics in Modern Liquid Biopsy Diagnostics. *Clin Chem.* 2021; 67(4):576-578.
401. **Scorilas A**, Panoutsopoulou K, Tsiakanikas P. The interplay between miR-1245a and BRCA2 in colorectal cancer. *Ann Transl Med.* 2020 Sep;8(17):1043.
402. Schmitt M, Renné T, **Scorilas A**. The kallikreins: old proteases with new clinical potentials. *Thromb Haemost.* 2013; 110(3):396-8.
403. **Scorilas A**. The effects of anticancer agents on cell apoptosis and on the expression of cancer-related genes. *Anticancer Agents Med Chem.* 2013; 14(3):341-2.
404. **Scorilas A**, Mavridis K, Magdolen V, Fritz H. Highlight: the 4th International Symposium on Kallikreins and Kallikrein-related peptidases. *Biol Chem.* 2012; 393(5):299-300.
405. **Scorilas A**, Mavridis K. Kallikrein-related peptidases (KLKs) as novel potential biomarkers in gastric cancer: An open yet challenging road lies ahead. *J Surg Oncol.* 2012; 105(3):223-4.

Projects

Patents

1. **Scorilas A**, Avgeris M, Thomaidis NS, Voulgaris N, Adamopoulos PG. Detection and mutational analysis of an RNA virus in an environmental sample. (International application No. PCT/EP2021/057316 - International filing date 22.03.2021).
2. **Scorilas A**, Diamandis EP. Novel BCL2 related proline rich protein (BPR). US Patent. No 09/953352; September 14, 2001.
3. **Scorilas A**, Diamandis EP. Human Ser/Arg-rich protein. US Patent. No 11757.48-US-P1; Jun. 8, 2000.
4. **Scorilas A**, Diamandis EP. Novel testis specific kinase substrate. US Patent. No 11757.47-US-P1; Jun. 8, 2000.

5. **Scorilas A**, Diamandis EP. Novel Adaptin Gene. Pending US Patent No 13780.58 deposited: 7/12/2000.

Selected Research Grants

1. Study of m6A epitranscriptome in bladder cancer (EpiRNA). Hellenic Foundation of Research and Innovation (H.F.R.I), 2023-, *Principal Investigator*.
2. Study of Non-Code RNA (ncRNAs) in Cancer Cells and solid Tumors. Study and Clinical Evaluation of Novel Molecular Cancer Biomarkers. Grant of Stavros Niarchos Foundation, 2017-
3. Identifying Biomarkers Through Translational Research For Prevention and Stratification of Colorectal Cancer (TRANSCOLONCAN). EU Grant, COST Action CA17118, 2018-
4. New diagnostic and therapeutic tools against multidrug resistant tumors. COST Action CA17104, EU Grant, 2018-
5. Identification and Evaluation of Novel BIOMarkers for Early Diagnosis, PROgnosis, and Treatment MONitoring of Breast and Prostate Cancers, through the Development of Hypersensitive Molecular Methodologies (BIOPROMO) (*Coordinator*). *Organization*: European Social Fund and Greek Ministry of Education (Thales), 2011-2015
6. INtegrating the emerging research Potential of the University of Athens Cancer Research Group in the European research area (INsPiRE). (*Partner and WP Coordinator*). *Organization*: Seven Framework Program (FP7), EU (2011-2014).
7. Expression analysis and study of a novel molecular marker for the laboratory diagnosis, prognosis and treatment response prediction for prostate cancer (*Coordinator*). *Organization*: Ministry of Health and Social Solidarity, 2008-2010.
8. Development of a new prognostic and monitoring method of colon and gastric carcinoma. (*Coordinator*). *Organization*: European Social Fund and General Secretary for Research and Technology of Greece (EPAN, PENED), 2005-2009.
9. Development of a novel molecular methodology for diagnosis, prognosis and treatment reposnse prediction of prostate cancer patients (*Coordinator*).*Organization*: General Secretary for Research and Technology of Greece (EPAN E&T Greece-Canada), 2005-2008.
10. Development and study of novel molecular biomarkers for diagnosis, prognosis and prediction of therapy response in prostate cancer (*Coordinator*).*Organization*:. European Social Fund and General Secretary for Research and Technology of Greece (EPAN

E&T Greece-Czech Republic), 2005-2007.

11. Development of a novel molecular method for diagnosis, prognosis, and prediction of therapy response in nasopharyngeal cancer (NPC) (*Coordinator*). *Organization*: European Social Fund and General Secretary for Research and Technology of Greece (EPAN E&T Greece-Tunisia), 2005-2007).
12. Health improvement in Serbia through reinforcement of biomedical science and technology. (*Partner*). *Organization*: Six Framework Program (FP6), EU, 2005-2008.
13. Development of a new molecular method for prediction of cytotoxic value of chemotherapeutic drugs through apoptosis induction. (*Coordinator*). *Organization*: European Social Fund and Greek Ministry of Education (EPEAEK II), 2004-2006.
14. Novel Prognostic and Predictive Cancer Markers. (*Partner*). *Organization*: National Institute of Health (NIH), USA, 2004-2006.
15. Development of a new prognostic and monitoring method of breast and ovarian cancer. (*Coordinator*). *Organization*: European Social Fund and General Secretary for Research and Technology of Greece (EPAN, PENED), 2002-2006.
16. Expression analysis and study of the role of *BCL2L12*, a newly identified Bcl-2 family member, in sensitivity versus resistance of tumor cells to death-ligand- and drug-induced apoptosis. (*Coordinator*). *Organization*: European Social Fund and General Secretary for Research and Technology of Greece (Greek – Spain Cooperation), 2002-2005.
17. Expression analysis of the novel gene, *SRA1*, in solid tumors: a new cancer biomarker? (*Coordinator*). *Organization*: European Social Fund and General Secretary for Research and Technology of Greece (Greek – Russian Cooperation), 2002-2004.
18. Determination of antimicrobial and cytostatic effect of dinuclear complexes of copper (II) and cobalt (III) with mixed substitutes. (*Coordinator*). *Organization*: European Social Fund and General Secretary for Research and Technology of Greece (Greek - Serbian Cooperation), 2001-2003.

Memberships

Distinctions and Awards

A. Major Awards and Distinctions

- *Ranked among the top 10 Researchers-Authors globally- in the field of Tumor Biomarkers, Clinical Biochemistry, Cancer Molecular Biology (Biomed Experts, Google Scholar).*

- *President of the International Society for Enzymology, 2016-2020*
- *National Academy of Clinical Biochemistry Award, Los Angeles, USA, 2012.*
- *E.K. Frey - E. Werle Promotion Prize, International Scientific Award, Munich, Germany, 2009.*
- *Guest Editor of 8 Highlight Issues of the Journals: Biological Chemistry, Thrombosis and Haemostasis, Current Chemical Biology, Anti-Cancer Agents in Medicinal Chemistry, International Scholarly Research Notices, Austin Proteomics, and Austin Journal of Molecular and Cellular Biology.*
- *"Dionysios Razis" Scientific Award, Athens, Greece, 2009.*
- *The World Metal of Freedom, American Biographical Institute, North Carolina, US, 2008.*
- *"Greek Society of Men of Letters" Scientific Award, Athens, Greece, 2008.*
- *Empeirikeion Grant Award, Athens, Greece, 2007.*
- *Elected Fellow of the International Academy of Clinical and Applied Thrombosis/Haemostasis, New York, US, 2004.*

Other Relevant Information *Referee for Grant Agencies and Scientific Journals*

1. European Research Council (ERC),
2. Horizon 2020
3. Seven Framework Program (FP7), European Union (Health, Cancer Section)
4. General Secretary for Research and Technology of Greece
5. Hellenic Foundation for Research and Innovation (HFRI)
6. Cancer Research UK
7. Health Research Board (HRB) of Ireland
8. Internal Grant Agency of Czech Republic
9. Internal Grant Agency of Romania
10. Dutch Internal Grant Agency
11. Internal Grant Agency of Romania

12. BBA - Molecular Cell
13. BBA Molecular Basis Disease
14. Biochemical Pharmacology
15. Biological Chemistry
16. BMC Cancer
17. BMC Molecular Biology
18. Breast Cancer Research
19. British Journal of cancer
20. British Journal of Pharmacology
21. Cancer Chemotherapy and Pharmacology
22. Cancer Epidemiology, Biomarkers & Prevention
23. Canadian Medical Association Journal -CMAJ Open
24. Cancer Letters

25. Cancer Research
26. Clinica Chimica Acta
27. Clinical Biochemistry
28. Clinical Cancer Research
29. Clinical Chemistry
30. Current Pharmaceutical Design
31. Disease Markers
32. Endocrinology
33. Expert Opinion on Emerging Drugs
34. Expert Review of Anticancer Therapy
35. Expert Review on Molecular Diagnostics
36. European Journal of Pharmacology
37. FEBS Journal
38. Future Oncology
39. Gene
40. Genome Medicine
41. Hormones Journal
42. In Vitro Cellular & Developmental Biology
43. International Journal of Cancer
44. ISRN Oncology
45. Journal of Experimental & Clinical Cancer Research
46. J Biological Research
47. J Cancer Science Therapy
48. J Clinical Endocrinology & Metabolism
49. J Medicinal Chemistry
50. J Surgical Oncology
51. Journal of Biomedicine and Biotechnology
52. Journal of Oncology
53. Journal of Photochem. and Photobiology A Chemistry
54. Mammalian Genome
55. Methods and Findings in Experimental and Clinical Pharmacology
56. Molecular Cancer
57. Molecular Oncology
58. Molecular and Cellular Biochemistry
59. Nature Reviews Urology
60. Oncogene
61. Protein Expression & Purification
62. Prostate Cancer
63. Talanta
64. The International Journal of Biochemistry & Cell Biology
65. The Protein Journal
66. The World Journal of Hypertension
67. Thrombosis and Haemostasis
68. Tumor Biology